



(72) LEE, SE-JIN, US

(71) THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE, US

(51) Int.Cl.⁶ A61K 38/18, A61K 31/185

(30) 1997/10/06 (08/946,092) US

(54) **UTILISATION DU FACTEUR DE DIFFERENTIATION DE LA
CROISSANCE (GDF-9) COMME CONTRACEPTIF**

(54) **USE OF GROWTH DIFFERENTIATION FACTOR-9 (GDF-9) AS
A CONTRACEPTIVE**

(57) L'invention se rapporte au facteur-9 de différenciation de la croissance (GDF-9) ainsi qu'à sa séquence polynucléotidique et à sa séquence d'acides aminés. L'invention concerne également un procédé pour freiner la maturation des oocytes au moyen d'inhibiteurs du GDF-9 ou par l'induction d'une réponse immunitaire au polypeptide du GDF-9 ou à ses fragments.

(57) Growth differentiation factor-9 (GDF-9) is disclosed along with its polynucleotide sequence and amino acid sequence. Also disclosed is a method for inhibiting oocyte maturation using GDF-9 inhibitors or by inducing an immune response to GDF-9 polypeptide or fragments thereof.

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 38/18, 31/185	A1	(11) International Publication Number: WO 99/17797 (43) International Publication Date: 15 April 1999 (15.04.99)
(21) International Application Number: PCT/US98/21199 (22) International Filing Date: 6 October 1998 (06.10.98) (30) Priority Data: 08/946,092 6 October 1997 (06.10.97) US (71) Applicant: THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE [US/US]; 720 Rutland Avenue, Baltimore, MD 21205 (US). (72) Inventor: LEE, Se-Jin; 6711 Chokeberry Road, Baltimore, MD 21209 (US). (74) Agent: HAILE, Lisa, A.; Fish & Richardson P.C., Suite 1400, 4225 Executive Square, La Jolla, CA 92037 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: USE OF GROWTH DIFFERENCIATION FACTOR-9 (GDF-9) AS A CONTRACEPTIVE (57) Abstract Growth differentiation factor-9 (GDF-9) is disclosed along with its polynucleotide sequence and amino acid sequence. Also disclosed is a method for inhibiting oocyte maturation using GDF-9 inhibitors or by inducing an immune response to GDF-9 polypeptide or fragments thereof.		

- 1 -

USE OF GROWTH DIFFERENTIATION FACTOR-9 (GDF-9)
AS A CONTRACEPTIVE

BACKGROUND OF THE INVENTION

5 1. *Field of the Invention*

The invention relates generally to growth factors and specifically to a new member of the transforming growth factor beta (TGF- β) superfamily, which is denoted, growth differentiation factor-9 (GDF-9) and methods of use as a contraceptive.

2. *Description of Related Art*

10 The transforming growth factor β (TGF- β) superfamily encompasses a group of structurally-related proteins which affect a wide range of differentiation processes during embryonic development. The family includes, Mullerian inhibiting substance (MIS), which is required for normal male sex development (Behringer, *et al.*, *Nature*, 345:167, 1990), *Drosophila* decapentaplegic (DPP) gene product, which is required for dorsal-
15 ventral axis formation and morphogenesis of the imaginal disks (Padgett, *et al.*, *Nature*, 325:81-84, 1987), the *Xenopus* Vg-1 gene product, which localizes to the vegetal pole of eggs ((Weeks, *et al.*, *Cell*, 51:861-867, 1987), the activins (Mason, *et al.*, *Biochem. Biophys. Res. Commun.*, 135:957-964, 1986), which can induce the formation of mesoderm and anterior structures in *Xenopus* embryos (Thomsen, *et al.*, *Cell*, 63:485,
20 1990), and the bone morphogenetic proteins (BMPs, osteogenin, OP-1) which can induce *de novo* cartilage and bone formation (Sampath, *et al.*, *J. Biol. Chem.*, 265:13198, 1990). The TGF- β s can influence a variety of differentiation processes, including adipogenesis, myogenesis, chondrogenesis, hematopoiesis, and epithelial cell differentiation (for review, see Massague, *Cell* 49:437, 1987).

- 2 -

The proteins of the TGF- β family are initially synthesized as a large precursor protein which subsequently undergoes proteolytic cleavage at a cluster of basic residues approximately 110-140 amino acids from the C-terminus. The C-terminal regions of the proteins are all structurally related and the different family members can be classified
5 into distinct subgroups based on the extent of their homology. Although the homologies within particular subgroups range from 70% to 90% amino acid sequence identity, the homologies between subgroups are significantly lower, generally ranging from only 20% to 50%. In each case, the active species appears to be a disulfide-linked dimer of C-terminal fragments. For most of the family members that have been studied, the
10 homodimeric species has been found to be biologically active, but for other family members, like the inhibins (Ling, *et al.*, *Nature*, 321:779, 1986) and the TGF- β s (Cheifetz, *et al.*, *Cell*, 48:409, 1987), heterodimers have also been detected, and these appear to have different biological properties than the respective homodimers.

The inhibins and activins were originally purified from follicular fluid and shown to have
15 counteracting effects on the release of follicle-stimulating hormone by the pituitary gland. Although the mRNAs for all three inhibin/activin subunits (α , β A and β B) have been detected in the ovary, none of these appear to be ovary-specific (Meunier, *et al.*, *Proc.Natl.Acad.Sci. USA*, 85:247, 1988). MIS has also been shown to be expressed by granulosa cells and the effects of MIS on ovarian development have been documented
20 both *in vivo* in transgenic mice expressing MIS ectopically (Behringer, *supra*) and *in vitro* in organ culture (Vigier, *et al.*, *Development*, 100:43, 1987).

Identification of new factors that are tissue-specific in their expression pattern will provide a greater understanding of that tissue's development and function.

- 3 -

SUMMARY OF THE INVENTION

The present invention provides a cell growth and differentiation factor, GDF-9, a polynucleotide sequence which encodes the factor and antibodies which are immunoreactive with the factor. This factor appears to relate to various cell proliferative disorders, especially those involving ovarian tumors, such as granulosa cell tumors. GDF-9 is exclusively expressed in oocytes and plays a role in maturation of oocytes.

Thus, in one embodiment, the invention provides a method for detecting a cell proliferative disorder of ovarian origin and which is associated with GDF-9. In another embodiment, the invention provides a method of treating a cell proliferative disorder associated with abnormal levels of expression of GDF-9, by suppressing or enhancing GDF-9 activity.

In another embodiment, the invention provides a method for inhibiting oocyte maturation. The method includes contacting oocytes with an inhibiting effective amount of an inhibitor of GDF-9, thereby inhibiting oocyte maturation as compared to untreated oocytes. Inhibition of oocyte maturation provides contraception for fertile female subjects.

The invention also provides a method for inducing an immune response in a subject to GDF-9 whereby oocyte maturation is inhibited, comprising administering to a subject GDF-9 polypeptide or immunogenic fragment thereof and inducing an anti-GDF-9 immune response in the subject.

- 4 -

BRIEF DESCRIPTION OF THE DRAWINGS

FIGURE 1 shows expression of GDF-9 mRNA in adult tissues.

FIGURES 2a-2c shows nucleotide and predicted amino acid sequence of GDF-9. Consensus N-glycosylation signals are denoted by plain boxes. The putative tetrabasic
5 processing sites are denoted by stippled boxes. The in-frame termination codons upstream of the putative initiating ATG and the consensus polyadenylation signals are underlined. The poly A tails are not shown. Numbers indicate nucleotide position relative to the 5' end.

FIGURES 3a-3b show the alignment of the C-terminal sequences of GDF-9 with other
10 members of the TGF- β family. The conserved cysteine residues are shaded. Dashes denote gaps introduced in order to maximize alignment.

FIGURES 4a-4b show amino acid homologies among the different members of the TGF- β superfamily. Numbers represent percent amino acid identities between each pair calculated from the first conserved cysteine to the C-terminus. Boxes represent homolo-
15 gies among highly-related members within particular subgroups.

FIGURES 5a-5c show the immunohistochemical localization of GDF-9 protein. Adjacent sections of an adult ovary were either stained with hematoxylin and eosin (FIGURE 5a) or incubated with immune (FIGURE 5b) or pre-immune (FIGURE 5c) serum at a dilution of 1:500. Anti-GDF-9 antiserum was prepared by expressing the C-
20 terminal portion of murine GDF-9 (residues 308-441) in bacteria, excising GDF-9 protein from preparative SDS gels, and immunizing rabbits. Sites of antibody binding were visualized using the Vectastain ABC kit (Vector Labs).

- 5 -

FIGURE 6 shows a comparison of the predicted amino acid sequences of murine (top lines) and human (bottom lines) GDF-9. Numbers represent amino acid positions relative to the N-termini. Vertical lines represent sequence identities. Dots represent gaps introduced in order to maximize the alignment. The clear box shows the predicted proteolytic processing sites. The shaded boxes show the cysteine residues in the mature region of the proteins. The bars at the bottom show a schematic of the pre-(clear) and mature (shaded) regions of GDF-9 with the percent sequence identities between the murine and human sequences shown below.

FIGURES 7a-7d show *in situ* hybridization to adult ovary sections using a GDF-9 RNA probe. [³⁵S]-labeled anti-sense (FIGURE 7a and 7c) or sense (FIGURE 7b and 7d) GDF-9 RNA probes were hybridized to adjacent paraffin-embedded sections of ovaries fixed in 4% paraformaldehyde. Sections were dipped in photographic emulsion, exposed, developed, and then stained with hematoxylin and eosin. Two representative fields are shown.

FIGURES 8a-8b show *in situ* hybridization to a postnatal day 4 ovary section using an antisense GDF-9 RNA probe. Sections were prepared as described for FIGURE 7. Following autoradiography and staining, the section was photographed under bright-field (FIGURE 8a) or dark-field (FIGURE 8b) illumination.

FIGURES 9a-9b show *in situ* hybridization to postnatal day 8 ovary sections using an antisense (FIGURE 9a) or sense (FIGURE 9b) GDF-9 RNA probe. Sections were prepared as described for FIGURE 7.

FIGURES 10a-10b show *in situ* hybridization to adult oviduct sections using an antisense (FIGURE 10a) or sense (FIGURE 10b) GDF-9 RNA probe. Sections were prepared as described for FIGURE 7.

- 6 -

FIGURES 11a-11b show *in situ* hybridization to an adult oviduct (0.5 days following fertilization) section using an antisense GDF-9 RNA probe. Sections were prepared as described for FIGURE 7. Following autoradiography and staining, the section was photographed under bright-field (FIGURE 11a) or dark-field (FIGURE 11b) illumination.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides a growth and differentiation factor, GDF-9 and a polynucleotide sequence encoding GDF-9. Unlike other members of the TGF- β superfamily, GDF-9 expression is highly tissue specific, being expressed in cells primarily in ovarian tissue. In one embodiment, the invention provides a method for detection of a cell proliferative disorder of the ovary, which is associated with GDF-9 expression. In another embodiment, the invention provides a method for treating a cell proliferative disorder associated with abnormal expression of GDF-9 by using an agent which suppresses or enhances GDF-9 activity. In another embodiment, the invention provides a method for inhibiting oocyte maturation.

Due to the expression of GDF-9 in the reproductive tract, there are a variety of applications using the polypeptide, polynucleotide and antibodies of the invention, related to contraception, fertility and pregnancy. GDF-9 could play a role in regulation of the menstrual cycle and, therefore, could be useful in various contraceptive regimens.

The TGF- β superfamily consists of multifunctional polypeptides that control proliferation, differentiation, and other functions in many cell types. Many of the peptides have regulatory, both positive and negative, effects on other peptide growth factors. The structural homology between the GDF-9 protein of this invention and the members of the TGF- β family, indicates that GDF-9 is a new member of the family of growth and differentiation factors. Based on the known activities of many of the other

- 7 -

members, it can be expected that GDF-9 will also possess biological activities that will make it useful as a diagnostic and therapeutic reagent.

For example, another regulatory protein that has been found to have structural homology with TGF- β is inhibin, a specific and potent polypeptide inhibitor of the pituitary secretion of FSH. Inhibin has been isolated from ovarian follicular fluid. Because of its suppression of FSH, inhibin has potential to be used as a contraceptive in both males and females. GDF-9 may possess similar biological activity since it is also an ovarian specific peptide. Inhibin has also been shown to be useful as a marker for certain ovarian tumors (Lappohn, *et al.*, *N. Engl. J. Med.*, 321:790, 1989). GDF-9 may also be useful as a marker for identifying primary and metastatic neoplasms of ovarian origin. Similarly, GDF-9 may be useful as an indicator of developmental anomalies in prenatal screening procedures.

Another peptide of the TGF- β family is MIS, produced by the testis and responsible for the regression of the Mullerian ducts in the male embryo. MIS has been shown to inhibit the growth of human ovarian cancer in nude mice (Donahoe, *et al.*, *Ann. Surg.*, 194:472, 1981). GDF-9 may function similarly and may, therefore, be useful as an anti-cancer agent, such as for the treatment of ovarian cancer.

GDF-9 may also function as a growth stimulatory factor and, therefore, be useful for the survival of various cell populations *in vitro*. In particular, if GDF-9 plays a role in oocyte maturation, it may be useful in *in vitro* fertilization procedures, e.g., in enhancing the success rate. Many of the members of the TGF- β family are also important mediators of tissue repair. TGF- β has been shown to have marked effects on the formation of collagen and causes a striking angiogenic response in the newborn mouse (Roberts, *et al.*, *Proc. Natl. Acad. Sci. USA*, 83:4167, 1986). GDF-9 may also have similar activities and may be useful in repair of tissue injury caused by trauma or burns for example.

- 8 -

The term "substantially pure" as used herein refers to GDF-9 which is substantially free of other proteins, lipids, carbohydrates or other materials with which it is naturally associated. One skilled in the art can purify GDF-9 using standard techniques for protein purification. The substantially pure polypeptide will yield a single major band on a non-reducing polyacrylamide gel. The purity of the GDF-9 polypeptide can also be determined by amino-terminal amino acid sequence analysis. GDF-9 polypeptide includes functional fragments of the polypeptide, as long as the activity of GDF-9 remains. Smaller peptides containing the biological activity of GDF-9 are included in the invention.

- 10 The invention provides polynucleotides encoding the GDF-9 protein. These polynucleotides include DNA, cDNA and RNA sequences which encode GDF-9. It is understood that all polynucleotides encoding all or a portion of GDF-9 are also included herein, as long as they encode a polypeptide with GDF-9 activity. Such polynucleotides include naturally occurring, synthetic, and intentionally manipulated polynucleotides.
- 15 For example, GDF-9 polynucleotide may be subjected to site-directed mutagenesis. The polynucleotide sequence for GDF-9 also includes antisense sequences. The polynucleotides of the invention include sequences that are degenerate as a result of the genetic code. There are 20 natural amino acids, most of which are specified by more than one codon. Therefore, all degenerate nucleotide sequences are included in the
- 20 invention as long as the amino acid sequence of GDF-9 polypeptide encoded by the nucleotide sequence is functionally unchanged.

Specifically disclosed herein is a cDNA sequence for GDF-9 which is 1712 base pairs in length and contains an open reading frame beginning with a methionine codon at nucleotide 29. The encoded polypeptide is 441 amino acids in length with a molecular weight of about 49.6 kD, as determined by nucleotide sequence analysis. The GDF-9 sequence contains a core of hydrophobic amino acids near the N-terminus, suggestive of a signal sequence for secretion. GDF-9 contains four potential N-glycosylation sites at asparagine residues 163, 229, 258, and 325 and a putative tetrabasic proteolytic

- 9 -

processing site (RRRR) at amino acids 303-306. The mature C-terminal fragment of GDF-9 is predicted to be 135 amino acids in length and have an unglycosylated molecular weight of about 15.6 kD, as determined by nucleotide sequence analysis. One skilled in the art can modify, or partially or completely remove the glycosyl groups from
5 the GDF-9 protein using standard techniques. Therefore, the functional protein or fragments thereof of the invention includes glycosylated, partially glycosylated and unglycosylated species of GDF-9.

The degree of sequence identity of GDF-9 with known TGF- β family members ranges from a minimum of 21% with Mullerian inhibiting substance (MIS) to a maximum of
10 34% with bone morphogenetic protein-4 (BMP-4). GDF-9 specifically disclosed herein differs from the known family members in its pattern of cysteine residues in the C-terminal region. GDF-9 lacks the fourth cysteine of the seven cysteines present in other family members; in place of cysteine at this position, the GDF-9 sequence contains a serine residue. This GDF-9 does not contain a seventh cysteine residue elsewhere in the
15 C-terminal region.

Minor modifications of the recombinant GDF-9 primary amino acid sequence may result in proteins which have substantially equivalent activity as compared to the GDF-9 polypeptide described herein. Such modifications may be deliberate, as by site-directed mutagenesis, or may be spontaneous. All of the polypeptides produced by these
20 modifications are included herein as long as the biological activity of GDF-9 still exists. Further, deletion of one or more amino acids can also result in a modification of the structure of the resultant molecule without significantly altering its biological activity. This can lead to the development of a smaller active molecule which would have broader utility. For example, one can remove amino or carboxy terminal amino acids which are
25 not required for GDF-9 biological activity.

- 10 -

The nucleotide sequence encoding the GDF-9 polypeptide of the invention includes the disclosed sequence and conservative variations thereof. The term "conservative variation" as used herein denotes the replacement of an amino acid residue by another, biologically similar residue. Examples of conservative variations include the substitution
5 of one hydrophobic residue such as isoleucine, valine, leucine or methionine for another, or the substitution of one polar residue for another, such as the substitution of arginine for lysine, glutamic for aspartic acids, or glutamine for asparagine, and the like. The term "conservative variation" also includes the use of a substituted amino acid in place of an unsubstituted parent amino acid provided that antibodies raised to the substituted
10 polypeptide also immunoreact with the unsubstituted polypeptide.

DNA sequences of the invention can be obtained by several methods. For example, the DNA can be isolated using hybridization techniques which are well known in the art. These include, but are not limited to: 1) hybridization of genomic or cDNA libraries with probes to detect homologous nucleotide sequences and 2) antibody screening of
15 expression libraries to detect cloned DNA fragments with shared structural features.

Preferably the GDF-9 polynucleotide of the invention is derived from a mammalian organism, and most preferably from a mouse, rat, or human. Screening procedures which rely on nucleic acid hybridization make it possible to isolate any gene sequence from any organism, provided the appropriate probe is available. Oligonucleotide probes, which
20 correspond to a part of the sequence encoding the protein in question, can be synthesized chemically. This requires that short, oligopeptide stretches of amino acid sequence must be known. The DNA sequence encoding the protein can be deduced from the genetic code, however, the degeneracy of the code must be taken into account. It is possible to perform a mixed addition reaction when the sequence is degenerate. This includes a
25 heterogeneous mixture of denatured double-stranded DNA. For such screening, hybridization is preferably performed on either single-stranded DNA or denatured double-stranded DNA. Hybridization is particularly useful in the detection of cDNA clones derived from sources where an extremely low amount of mRNA sequences

- 11 -

relating to the polypeptide of interest are present. In other words, by using stringent hybridization conditions directed to avoid non-specific binding, it is possible, for example, to allow the autoradiographic visualization of a specific cDNA clone by the hybridization of the target DNA to that single probe in the mixture which is its complete
5 complement (Wallace, *et al.*, *Nucl. Acid Res.*, 9:879, 1981).

The development of specific DNA sequences encoding GDF-9 can also be obtained by:
1) isolation of double-stranded DNA sequences from the genomic DNA; 2) chemical manufacture of a DNA sequence to provide the necessary codons for the polypeptide of interest; and 3) *in vitro* synthesis of a double-stranded DNA sequence by reverse
10 transcription of mRNA isolated from a eukaryotic donor cell. In the latter case, a double-stranded DNA complement of mRNA is eventually formed which is generally referred to as cDNA.

Of the three above-noted methods for developing specific DNA sequences for use in recombinant procedures, the isolation of genomic DNA isolates is the least common.
15 This is especially true when it is desirable to obtain the microbial expression of mammalian polypeptides due to the presence of introns.

The synthesis of DNA sequences is frequently the method of choice when the entire sequence of amino acid residues of the desired polypeptide product is known. When the entire sequence of amino acid residues of the desired polypeptide is not known, the direct
20 synthesis of DNA sequences is not possible and the method of choice is the synthesis of cDNA sequences. Among the standard procedures for isolating cDNA sequences of interest is the formation of plasmid- or phage-carrying cDNA libraries which are derived from reverse transcription of mRNA which is abundant in donor cells that have a high level of genetic expression. When used in combination with polymerase chain reaction
25 technology, even rare expression products can be cloned. In those cases where significant portions of the amino acid sequence of the polypeptide are known, the production of labeled single or double-stranded DNA or RNA probe sequences

- 12 -

duplicating a sequence putatively present in the target cDNA may be employed in DNA/DNA hybridization procedures which are carried out on cloned copies of the cDNA which have been denatured into a single-stranded form (Jay, *et al.*, *Nucl. Acid Res.*, 11:2325, 1983).

- 5 A cDNA expression library, such as lambda gt11, can be screened indirectly for GDF-9 peptides having at least one epitope, using antibodies specific for GDF-9. Such antibodies can be either polyclonally or monoclonally derived and used to detect expression product indicative of the presence of GDF-9 cDNA.

DNA sequences encoding GDF-9 can be expressed *in vitro* by DNA transfer into a
10 suitable host cell. "Host cells" are cells in which a vector can be propagated and its DNA expressed. The term also includes any progeny of the subject host cell. It is understood that all progeny may not be identical to the parental cell since there may be mutations that occur during replication. However, such progeny are included when the term "host cell" is used. Methods of stable transfer, meaning that the foreign DNA is continuously
15 maintained in the host, are known in the art.

In the present invention, the GDF-9 polynucleotide sequences may be inserted into a recombinant expression vector. The term "recombinant expression vector" refers to a plasmid, virus or other vehicle known in the art that has been manipulated by insertion or incorporation of the GDF-9 genetic sequences. Such expression vectors contain a
20 promoter sequence which facilitates the efficient transcription of the inserted genetic sequence of the host. The expression vector typically contains an origin of replication, a promoter, as well as specific genes which allow phenotypic selection of the transformed cells. Vectors suitable for use in the present invention include, but are not limited to the T7-based expression vector for expression in bacteria (Rosenberg, *et al.*,
25 *Gene*, 56:125, 1987), the pMSXND expression vector for expression in mammalian cells (Lee and Nathans, *J. Biol. Chem.*, 263:3521, 1988) and baculovirus-derived vectors for expression in insect cells. The DNA segment can be present in the vector operably

- 13 -

linked to regulatory elements, for example, a promoter (e.g., T7, metallothionein I, or polyhedrin promoters).

Polynucleotide sequences encoding GDF-9 can be expressed in either prokaryotes or eukaryotes. Hosts can include microbial, yeast, insect and mammalian organisms.

5 Methods of expressing DNA sequences having eukaryotic or viral sequences in prokaryotes are well known in the art. Biologically functional viral and plasmid DNA vectors capable of expression and replication in a host are known in the art. Such vectors are used to incorporate DNA sequences of the invention.

Transformation of a host cell with recombinant DNA may be carried out by conventional

10 techniques as are well known to those skilled in the art. Where the host is prokaryotic, such as *E. coli*, competent cells which are capable of DNA uptake can be prepared from cells harvested after exponential growth phase and subsequently treated by the CaCl_2 method using procedures well known in the art. Alternatively, MgCl_2 or RbCl can be used. Transformation can also be performed after forming a protoplast of the host cell

15 if desired.

When the host is a eukaryote, such methods of transfection of DNA as calcium phosphate co-precipitates, conventional mechanical procedures such as microinjection, electroporation, insertion of a plasmid encased in liposomes, or virus vectors may be used. Eukaryotic cells can also be cotransformed with DNA sequences encoding the

20 GDF-9 of the invention, and a second foreign DNA molecule encoding a selectable phenotype, such as the herpes simplex thymidine kinase gene. Another method is to use a eukaryotic viral vector, such as simian virus 40 (SV40) or bovine papilloma virus, to transiently infect or transform eukaryotic cells and express the protein. (see for example, *Eukaryotic Viral Vectors*, Cold Spring Harbor Laboratory, Gluzman ed., 1982).

- 14 -

Isolation and purification of microbial expressed polypeptide, or fragments thereof, provided by the invention, may be carried out by conventional means including preparative chromatography and immunological separations involving monoclonal or polyclonal antibodies.

- 5 The invention includes antibodies immunoreactive with GDF-9 polypeptide or functional fragments thereof. Antibody which consists essentially of pooled monoclonal antibodies with different epitopic specificities, as well as distinct monoclonal antibody preparations are provided. Monoclonal antibodies are made from antigen containing fragments of the protein by methods well known to those skilled in the art (Kohler, *et al.*, *Nature*,
10 256:495, 1975). The term antibody as used in this invention is meant to include intact molecules as well as fragments thereof, such as Fab and F(ab')₂, which are capable of binding an epitopic determinant on GDF-9.

The preparation of polyclonal antibodies is well-known to those skilled in the art. See, for example, Green *et al.*, *Production of Polyclonal Antisera*, in IMMUNOCHEMICAL
15 PROTOCOLS (Manson, ed.), pages 1-5 (Humana Press 1992); Coligan *et al.*, *Production of Polyclonal Antisera in Rabbits, Rats, Mice and Hamsters*, in CURRENT PROTOCOLS IN IMMUNOLOGY, section 2.4.1 (1992), which are hereby incorporated by reference.

The preparation of monoclonal antibodies likewise is conventional. See, for example,
20 Kohler & Milstein, *Nature* 256:495 (1975); Coligan *et al.*, sections 2.5.1-2.6.7; and Harlow *et al.*, ANTIBODIES: A LABORATORY MANUAL, page 726 (Cold Spring Harbor Pub. 1988), which are hereby incorporated by reference. Briefly, monoclonal antibodies can be obtained by injecting mice with a composition comprising an antigen, verifying the presence of antibody production by removing a serum sample, removing
25 the spleen to obtain B lymphocytes, fusing the B lymphocytes with myeloma cells to produce hybridomas, cloning the hybridomas, selecting positive clones that produce antibodies to the antigen, and isolating the antibodies from the hybridoma cultures.

- 15 -

Monoclonal antibodies can be isolated and purified from hybridoma cultures by a variety of well-established techniques. Such isolation techniques include affinity chromatography with Protein-A Sepharose, size-exclusion chromatography, and ion-exchange chromatography. See, e.g., Coligan *et al.*, sections 2.7.1-2.7.12 and sections 5 2.9.1-2.9.3; Barnes *et al.*, *Purification of Immunoglobulin G (IgG)*, in METHODS IN MOLECULAR BIOLOGY, VOL. 10, pages 79-104 (Humana Press 1992).

Methods of *in vitro* and *in vivo* multiplication of monoclonal antibodies is well-known to those skilled in the art. Multiplication *in vitro* may be carried out in suitable culture media such as Dulbecco's Modified Eagle Medium or RPMI 1640 medium, optionally 10 replenished by a mammalian serum such as fetal calf serum or trace elements and growth-sustaining supplements such as normal mouse peritoneal exudate cells, spleen cells, bone marrow macrophages. Production *in vitro* provides relatively pure antibody preparations and allows scale-up to yield large amounts of the desired antibodies. Large scale hybridoma cultivation can be carried out by homogenous suspension culture in an 15 airlift reactor, in a continuous stirrer reactor, or in immobilized or entrapped cell culture. Multiplication *in vivo* may be carried out by injecting cell clones into mammals histocompatible with the parent cells, e.g., osyngeneic mice, to cause growth of antibody-producing tumors. Optionally, the animals are primed with a hydrocarbon, especially oils such as pristane (tetramethylpentadecane) prior to injection. After one to three 20 weeks, the desired monoclonal antibody is recovered from the body fluid of the animal.

Therapeutic applications for antibodies disclosed herein are also part of the present invention. For example, antibodies of the present invention may also be derived from subhuman primate antibody. General techniques for raising therapeutically useful antibodies in baboons can be found, for example, in Goldenberg *et al.*, International 25 Patent Publication WO 91/11465 (1991) and Losman *et al.*, *Int. J. Cancer* 46:310 (1990), which are hereby incorporated by reference.

- 16 -

A therapeutically useful anti-GDF-9 antibody may be derived from a "humanized" monoclonal antibody. Humanized monoclonal antibodies are produced by transferring mouse complementarity determining regions from heavy and light variable chains of the mouse immunoglobulin into a human variable domain, and then substituting human
5 residues in the framework regions of the murine counterparts. The use of antibody components derived from humanized monoclonal antibodies obviates potential problems associated with the immunogenicity of murine constant regions. General techniques for cloning murine immunoglobulin variable domains are described, for example, by Orlandi *et al.*, *Proc. Nat'l Acad. Sci. USA* 86:3833 (1989), which is hereby incorporated in its
10 entirety by reference. Techniques for producing humanized monoclonal antibodies are described, for example, by Jones *et al.*, *Nature* 321: 522 (1986); Riechmann *et al.*, *Nature* 332: 323 (1988); Verhoeyen *et al.*, *Science* 239: 1534 (1988); Carter *et al.*, *Proc. Nat'l Acad. Sci. USA* 89: 4285 (1992); Sandhu, *Crit. Rev. Biotech.* 12: 437 (1992); and Singer *et al.*, *J. Immunol.* 150: 2844 (1993), which are hereby incorporated by reference.

15 Antibodies of the invention also may be derived from human antibody fragments isolated from a combinatorial immunoglobulin library. See, for example, Barbas *et al.*, *METHODS: A COMPANION TO METHODS IN ENZYMOLOGY*, VOL. 2, page 119 (1991); Winter *et al.*, *Ann. Rev. Immunol.* 12: 433 (1994), which are hereby incorporated by reference. Cloning and expression vectors that are useful for producing a human
20 immunoglobulin phage library can be obtained, for example, from STRATAGENE Cloning Systems (La Jolla, CA).

In addition, antibodies of the present invention may be derived from a human monoclonal antibody. Such antibodies are obtained from transgenic mice that have been "engineered" to produce specific human antibodies in response to antigenic challenge.
25 In this technique, elements of the human heavy and light chain loci are introduced into strains of mice derived from embryonic stem cell lines that contain targeted disruptions of the endogenous heavy and light chain loci. The transgenic mice can synthesize human antibodies specific for human antigens, and the mice can be used to produce human

- 17 -

antibody-secreting hybridomas. Methods for obtaining human antibodies from transgenic mice are described by Green *et al.*, *Nature Genet.* 7:13 (1994); Lonberg *et al.*, *Nature* 368:856 (1994); and Taylor *et al.*, *Int. Immunol.* 6:579 (1994), which are hereby incorporated by reference.

- 5 Antibody fragments of the present invention can be prepared by proteolytic hydrolysis of the antibody or by expression in *E. coli* of DNA encoding the fragment. Antibody fragments can be obtained by pepsin or papain digestion of whole antibodies by conventional methods. For example, antibody fragments can be produced by enzymatic cleavage of antibodies with pepsin to provide a 5S fragment denoted F(ab')₂. This
10 fragment can be further cleaved using a thiol reducing agent, and optionally a blocking group for the sulfhydryl groups resulting from cleavage of disulfide linkages, to produce 3.5S Fab' monovalent fragments. Alternatively, an enzymatic cleavage using pepsin produces two monovalent Fab' fragments and an Fc fragment directly. These methods are described, for example, by Goldenberg, U.S. patents No. 4,036,945 and No.
15 4,331,647, and references contained therein. These patents are hereby incorporated in their entireties by reference. *See also* Nisonhoff *et al.*, *Arch. Biochem. Biophys.* 89:230 (1960); Porter, *Biochem. J.* 73:119 (1959); Edelman *et al.*, *METHODS IN ENZYMOLOGY*, VOL. 1, page 422 (Academic Press 1967); and Coligan *et al.* at sections 2.8.1-2.8.10 and 2.10.1-2.10.4.
- 20 Other methods of cleaving antibodies, such as separation of heavy chains to form monovalent light-heavy chain fragments, further cleavage of fragments, or other enzymatic, chemical, or genetic techniques may also be used, so long as the fragments bind to the antigen that is recognized by the intact antibody.

For example, Fv fragments comprise an association of V_H and V_L chains. This
25 association may be noncovalent, as described in Inbar *et al.*, *Proc. Nat'l Acad. Sci. USA* 69:2659 (1972). Alternatively, the variable chains can be linked by an intermolecular disulfide bond or cross-linked by chemicals such as glutaraldehyde. *See, e.g.*, Sandhu,

- 18 -

supra. Preferably, the Fv fragments comprise V_H and V_L chains connected by a peptide linker. These single-chain antigen binding proteins (sFv) are prepared by constructing a structural gene comprising DNA sequences encoding the V_H and V_L domains connected by an oligonucleotide. The structural gene is inserted into an expression vector, which
5 is subsequently introduced into a host cell such as *E. coli*. The recombinant host cells synthesize a single polypeptide chain with a linker peptide bridging the two V domains. Methods for producing sFvs are described, for example, by Whitlow *et al.*, METHODS: A COMPANION TO METHODS IN ENZYMOLOGY, VOL. 2, page 97 (1991); Bird *et al.*, *Science* 242:423-426 (1988); Ladner *et al.*, U.S. patent No. 4,946,778; Pack *et al.*,
10 *Bio/Technology* 11: 1271-77 (1993); and Sandhu, *supra*.

Another form of an antibody fragment is a peptide coding for a single complementarity-determining region (CDR). CDR peptides ("minimal recognition units") can be obtained by constructing genes encoding the CDR of an antibody of interest. Such genes are prepared, for example, by using the polymerase chain reaction to synthesize the variable
15 region from RNA of antibody-producing cells. See, for example, Larrick *et al.*, METHODS: A COMPANION TO METHODS IN ENZYMOLOGY, VOL. 2, page 106 (1991).

The term "cell-proliferative disorder" denotes malignant as well as non-malignant cell populations which often appear to differ from the surrounding tissue both
20 morphologically and genotypically. The GDF-9 polynucleotide that is an antisense molecule is useful in treating malignancies of the various organ systems, particularly, for example, the ovaries. Essentially, any disorder which is etiologically linked to altered expression of GDF-9 could be considered susceptible to treatment with a GDF-9 suppressing reagent.

25 The invention provides a method for detecting a cell proliferative disorder of the ovary which comprises contacting an anti-GDF-9 antibody with a cell suspected of having a GDF-9 associated disorder and detecting binding to the antibody. The antibody reactive

- 19 -

with GDF-9 is labeled with a compound which allows detection of binding to GDF-9. For purposes of the invention, an antibody specific for GDF-9 polypeptide may be used to detect the level of GDF-9 in biological fluids and tissues. Any specimen containing a detectable amount of antigen can be used. A preferred sample of this invention is tissue
5 of ovarian origin, specifically tissue containing granulosa cells or ovarian follicular fluid. The level of GDF-9 in the suspect cell can be compared with the level in a normal cell to determine whether the subject has a GDF-9-associated cell proliferative disorder. Preferably the subject is human.

In another embodiment, the invention provides a contraceptive method which includes
10 inhibiting oocyte maturation. The method comprises contacting oocytes with an inhibiting effective amount of an inhibitor of GDF-9, thereby inhibiting oocyte maturation as compared to untreated oocytes. The term "inhibiting effective amount" as used herein means that amount of an inhibitor of GDF-9 that reduces maturation of an oocyte by about 50%, more preferably by about 75%, and most preferably by about 95%.
15 One of skill in the art could use any of several methods for determining whether the amount of inhibitor of GDF-9 is effective. For example, maturation of an oocyte results in ovulation, therefore, prevention of ovulation is indicative of an effective amount. For a period just prior to ovulation, a female's body temperature increases, indicating a fertile period. An absence of a change in body temperature is indicative of prevention of oocyte
20 maturation. Alternatively, one could measure the level of serum progesterone (see Example 6) in the subject prior to and following treatment with the inhibitor of GDF-9, where a low level of progesterone maintained throughout the period is indicative of inhibition of maturation. Levels of luteinizing hormone (LH) generally increase at the time of ovulation as well, and continuous low levels of LH can serve as an indicator of
25 inhibition of maturation of oocytes as well. Other events associated with ovulation can be monitored in a similar manner and will be known to those of skill in the art.

An "inhibitor of GDF-9" as used herein, refers to GDF-antibodies or fragments thereof as described above, antisense molecules, or peptide or peptidomimetics of GDF-9

- 20 -

polypeptide, for example. Other small molecules or chemical compounds may also be GDF-9 inhibitors. Also included are compounds identified using combinatorial chemistry methods for identifying chemical compounds that bind to GDF-9 or GDF-9 receptor. Preferably, when the inhibitor is a GDF-9 antibody or fragment thereof, the
5 antibody is administered in a dose range of 0.1 ug to 100 mg. Preferably, the inhibitor is administered *in vivo* and preferably, the subject is a mammal, such as a human. The term "contacting" refers to administering the GDF-9 inhibitor in such a way that the inhibitor inhibits GDF-9. Methods of administration are described in detail below.

The method of the invention is also useful for inducing an immune response in a subject
10 to GDF-9 whereby oocyte maturation is inhibited, comprising administering to a subject GDF-9 polypeptide or immunogenic fragment thereof and inducing an anti-GDF-9 immune response in the subject. Methods of producing immunogenic fragments of a polypeptide are well known in the art.

Polypeptides or peptides, including GDF-9 variants useful for the present invention
15 comprise analogs, homologs, muteins and mimetics of GDF-9 that retain the ability to induce a specific immune response to GDF-9 or to inhibit oocyte maturation. Peptides of GDF-9 refer to portions of the amino acid sequence of GDF-9 that also retain this ability. The variants can be generated directly from GDF-9 itself by chemical modification, by proteolytic enzyme digestion, or by combinations thereof. Additionally,
20 genetic engineering techniques, as well as methods of synthesizing polypeptides directly from amino acid residues, can be employed.

Peptides of the invention can be synthesized by such commonly used methods as t-BOC or FMOC protection of alpha-amino groups. Both methods involve stepwise syntheses whereby a single amino acid is added at each step starting from the C terminus of the
25 peptide (See, Coligan, *et al.*, *Current Protocols in Immunology*, Wiley Interscience, 1991, Unit 9). Peptides of the invention can also be synthesized by the well known solid phase peptide synthesis methods described Merrifield, *J. Am. Chem. Soc.*, 85:2149,

- 21 -

1962), and Stewart and Young, *Solid Phase Peptides Synthesis*, (Freeman, San Francisco, 1969, pp.27-62), using a copoly(styrene-divinylbenzene) containing 0.1-1.0 mMol amines/g polymer. On completion of chemical synthesis, the peptides can be deprotected and cleaved from the polymer by treatment with liquid HF-10% anisole for about 1/4-1
5 hours at 0°C. After evaporation of the reagents, the peptides are extracted from the polymer with 1% acetic acid solution which is then lyophilized to yield the crude material. This can normally be purified by such techniques as gel filtration on Sephadex G-15 using 5% acetic acid as a solvent. Lyophilization of appropriate fractions of the column will yield the homogeneous peptide or peptide derivatives, which can then be
10 characterized by such standard techniques as amino acid analysis, thin layer chromatography, high performance liquid chromatography, ultraviolet absorption spectroscopy, molar rotation, solubility, and quantitated by the solid phase Edman degradation. Alternatively, peptides can be produced by recombinant methods.

The term "substantially purified" as used herein refers to a molecule, such as a peptide
15 that is substantially free of other proteins, lipids, carbohydrates, nucleic acids, and other biological materials with which it is naturally associated. For example, a substantially pure molecule, such as a polypeptide, can be at least 60%, by dry weight, the molecule of interest. One skilled in the art can purify GDF-9 peptides using standard protein purification methods and the purity of the polypeptides can be determined using standard
20 methods including, *e.g.*, polyacrylamide gel electrophoresis (*e.g.*, SDS-PAGE), column chromatography (*e.g.*, high performance liquid chromatography (HPLC)), and amino-terminal amino acid sequence analysis.

Non-peptide compounds that mimic the binding and function of GDF-9 ("mimetics") can be produced by the approach outlined in Saragovi *et al.*, *Science* 253: 792-95 (1991).
25 Mimetics are molecules which mimic elements of protein secondary structure. See, for example, Johnson *et al.*, "Peptide Turn Mimetics," in BIOTECHNOLOGY AND PHARMACY, Pezzuto *et al.*, Eds., (Chapman and Hall, New York 1993). The underlying rationale behind the use of peptide mimetics is that the peptide backbone of

- 22 -

proteins exists chiefly to orient amino acid side chains in such a way as to facilitate molecular interactions. For the purposes of the present invention, appropriate mimetics can be considered to be the equivalent of GDF-9 itself.

Longer peptides can be produced by the "native chemical" ligation technique which links
5 together peptides (Dawson, *et al.*, *Science*, 266:776, 1994). Variants can be created by recombinant techniques employing genomic or cDNA cloning methods. Site-specific and region-directed mutagenesis techniques can be employed. See CURRENT PROTOCOLS IN MOLECULAR BIOLOGY vol. 1, ch. 8 (Ausubel *et al.* eds., J. Wiley & Sons 1989 & Supp. 1990-93); PROTEIN ENGINEERING (Oxender & Fox eds., A.
10 Liss, Inc. 1987). In addition, linker-scanning and PCR-mediated techniques can be employed for mutagenesis. See PCR TECHNOLOGY (Erlich ed., Stockton Press 1989); CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, vols. 1 & 2, *supra*. Protein sequencing, structure and modeling approaches for use with any of the above techniques are disclosed in PROTEIN ENGINEERING, *loc. cit.*, and CURRENT PROTOCOLS IN
15 MOLECULAR BIOLOGY, vols. 1 & 2, *supra*.

The invention also includes various pharmaceutical compositions that prevent maturation of an oocyte. The pharmaceutical compositions according to the invention are prepared by bringing an antibody against GDF-9, a peptide or peptide derivative of GDF-9, a GDF-9 mimetic, or a GDF-9-binding agent according to the present invention into a form
20 suitable for administration to a subject using carriers, excipients and additives or auxiliaries. Frequently used carriers or auxiliaries include magnesium carbonate, titanium dioxide, lactose, mannitol and other sugars, talc, milk protein, gelatin, starch, vitamins, cellulose and its derivatives, animal and vegetable oils, polyethylene glycols and solvents, such as sterile water, alcohols, glycerol and polyhydric alcohols.
25 Intravenous vehicles include fluid and nutrient replenishers. Preservatives include antimicrobial, anti-oxidants, chelating agents and inert gases. Other pharmaceutically acceptable carriers include aqueous solutions, non-toxic excipients, including salts, preservatives, buffers and the like, as described, for instance, in *Remington's*

- 23 -

Pharmaceutical Sciences, 15th ed. Easton: Mack Publishing Co., 1405-1412, 1461-1487 (1975) and *The National Formulary XIV.*, 14th ed. Washington: American Pharmaceutical Association (1975), the contents of which are hereby incorporated by reference. The pH and exact concentration of the various components of the pharmaceutical composition are adjusted according to routine skills in the art. See *Goodman and Gilman's The Pharmacological Basis for Therapeutics* (7th ed.).

The methods involves administering to a subject a therapeutically or inhibiting effective dose of a pharmaceutical composition containing the compounds of the present invention and a pharmaceutically acceptable carrier. "Administering" the pharmaceutical composition of the present invention may be accomplished by any means known to the skilled artisan. By "subject" is meant any mammal, preferably a human.

The pharmaceutical compositions are preferably prepared and administered in dose units. Solid dose units are tablets, capsules and suppositories. For treatment of a patient, depending on activity of the compound, manner of administration, nature and severity of the disorder, age and body weight of the patient, different daily doses are necessary. Under certain circumstances, however, higher or lower daily doses may be appropriate. The administration of the daily dose can be carried out both by single administration in the form of an individual dose unit or else several smaller dose units and also by multiple administration of subdivided doses at specific intervals.

The pharmaceutical compositions according to the invention are in general administered topically, intravenously, orally or parenterally or as implants, but even rectal use is possible in principle. Suitable solid or liquid pharmaceutical preparation forms are, for example, granules, powders, tablets, coated tablets, (micro)capsules, suppositories, syrups, emulsions, suspensions, creams, aerosols, drops or injectable solution in ampule form and also preparations with protracted release of active compounds, in whose preparation excipients and additives and/or auxiliaries such as disintegrants, binders, coating agents, swelling agents, lubricants, flavorings, sweeteners or solubilizers are

- 24 -

customarily used as described above. The pharmaceutical compositions are suitable for use in a variety of drug delivery systems. For a brief review of present methods for drug delivery, see Langer, *Science*, 249: 1527-1533 (1990), which is incorporated herein by reference.

- 5 The pharmaceutical compositions according to the invention may be administered locally or systemically. By "therapeutically effective dose" is meant the quantity of a compound according to the invention necessary to prevent, to cure or at least partially arrest the symptoms of the disease and its complications. An "inhibiting effective amount" of GDF-9 inhibitor has been defined above for use as in contraception regimes. Amounts
10 effective for this use will, of course, depend on the severity of the disease and the weight and general state of the patient. Typically, dosages used *in vitro* may provide useful guidance in the amounts useful for *in situ* administration of the pharmaceutical composition, and animal models may be used to determine effective dosages for treatment of particular disorders. Various considerations are described, *e.g.*, in Gilman
15 *et al.* (eds.) (1990) GOODMAN AND GILMAN'S: THE PHARMACOLOGICAL BASES OF THERAPEUTICS, 8th ed., Pergamon Press; and REMINGTON'S PHARMACEUTICAL SCIENCES, 17th ed. (1990), Mack Publishing Co., Easton, Pa., each of which is herein incorporated by reference.

The pharmaceutical compositions of the invention may also be delivered by a slow
20 release vehicle. Compounds of the invention can be further diluted by addition of suspending medium or other biologically acceptable carrier to obtain injectable or implantable slow release formulations of any therapeutically effective total dosage. One approach which has been used to provide controlled release compositions for drug delivery is liposome encapsulation. Among the main types of liposomes, multivesicular
25 liposomes (Kim, *et al.*, *Biochim. Biophys. Acta*; 728:339-348, 1983), are uniquely different from unilamellar liposomes (Huang, *Biochemistry*; 8:334-352, 1969; Kim, *et al.*, *Biochim. Biophys. Acta*; 646:1-10, 1981), multilamellar liposomes (Bangham, *et al.*, *J. Mol. Bio.*, 13:238-252, 1965), and stable plurilamellar liposomes (U.S. Patent No.

- 25 -

4,522,803). U.S. Patent No. 5,077,056 discloses studies that show the rate of release of the encapsulated biological agent from liposomes into an aqueous environment can be modulated by introducing protonophores or ionophores into liposomes to create a membrane potential. In addition, a method is known (U.S. Patent No. 5,186,941) for
5 controlling the release rate of drugs from vesicle compositions wherein the liposomes containing a therapeutic agent encapsulated are suspended in a solution containing sufficient solute to provide an osmolarity substantially isotonic with respect to that of the solution within the vesicles, and hypertonic with respect to physiological saline. In multivesicular liposomes, it is also known (WO 96/08253) to control the rate of release
10 of active agents by introducing an osmotic spacer into the aqueous solution in which the active agent is dissolved prior to formation of the multivesicular liposomes.

The antibodies of the invention can be used in any subject in which it is desirable to administer *in vitro* or *in vivo* immunodiagnosis or immunotherapy. The antibodies of the invention are suited for use, for example, in immunoassays in which they can be utilized
15 in liquid phase or bound to a solid phase carrier. In addition, the antibodies in these immunoassays can be detectably labeled in various ways. Examples of types of immunoassays which can utilize antibodies of the invention are competitive and non-competitive immunoassays in either a direct or indirect format. Examples of such immunoassays are the radioimmunoassay (RIA) and the sandwich (immunometric) assay.
20 Detection of the antigens using the antibodies of the invention can be done utilizing immunoassays which are run in either the forward, reverse, or simultaneous modes, including immunohistochemical assays on physiological samples. Those of skill in the art will know, or can readily discern, other immunoassay formats without undue experimentation.

25 The antibodies of the invention can be bound to many different carriers and used to detect the presence of an antigen comprising the polypeptide of the invention. Examples of well-known carriers include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylases, natural and modified celluloses, polyacrylamides, agaroses and

- 26 -

magnetite. The nature of the carrier can be either soluble or insoluble for purposes of the invention. Those skilled in the art will know of other suitable carriers for binding antibodies, or will be able to ascertain such, using routine experimentation.

There are many different labels and methods of labeling known to those of ordinary skill
5 in the art. Examples of the types of labels which can be used in the present invention include enzymes, radioisotopes, fluorescent compounds, colloidal metals, chemiluminescent compounds, phosphorescent compounds, and bioluminescent compounds. Those of ordinary skill in the art will know of other suitable labels for binding to the antibody, or will be able to ascertain such, using routine experimentation.

10 Another technique which may also result in greater sensitivity consists of coupling the antibodies to low molecular weight haptens. These haptens can then be specifically detected by means of a second reaction. For example, it is common to use such haptens as biotin, which reacts with avidin, or dinitrophenyl, puridoxal, and fluorescein, which can react with specific antihapten antibodies.

15 In using the monoclonal antibodies of the invention for the *in vivo* detection of antigen, the detectably labeled antibody is given a dose which is diagnostically effective. The term "diagnostically effective" means that the amount of detectably labeled monoclonal antibody is administered in sufficient quantity to enable detection of the site having the antigen comprising a polypeptide of the invention for which the monoclonal antibodies
20 are specific.

The concentration of detectably labeled monoclonal antibody which is administered should be sufficient such that the binding to those cells having the polypeptide is detectable compared to the background. Further, it is desirable that the detectably labeled monoclonal antibody be rapidly cleared from the circulatory system in order to
25 give the best target-to-background signal ratio.

- 27 -

As a rule, the dosage of detectably labeled monoclonal antibody for *in vivo* diagnosis will vary depending on such factors as age, sex, and extent of disease of the individual. Such dosages may vary, for example, depending on whether multiple injections are given, antigenic burden, and other factors known to those of skill in the art.

- 5 For *in vivo* diagnostic imaging, the type of detection instrument available is a major factor in selecting a given radioisotope. The radioisotope chosen must have a type of decay which is detectable for a given type of instrument. Still another important factor in selecting a radioisotope for *in vivo* diagnosis is that deleterious radiation with respect to the host is minimized. Ideally, a radioisotope used for *in vivo* imaging will lack a
10 particle emission, but produce a large number of photons in the 140-250 keV range, which may readily be detected by conventional gamma cameras.

For *in vivo* diagnosis radioisotopes may be bound to immunoglobulin either directly or indirectly by using an intermediate functional group. Intermediate functional groups which often are used to bind radioisotopes which exist as metallic ions to
15 immunoglobulins are the bifunctional chelating agents such as diethylenetriaminepentaacetic acid (DTPA) and ethylenediaminetetraacetic acid (EDTA) and similar molecules. Typical examples of metallic ions which can be bound to the monoclonal antibodies of the invention are ^{111}In , ^{97}Ru , ^{67}Ga , ^{68}Ga , ^{72}As , ^{89}Zr , and ^{201}Tl .

The monoclonal antibodies of the invention can also be labeled with a paramagnetic
20 isotope for purposes of *in vivo* diagnosis, as in magnetic resonance imaging (MRI) or electron spin resonance (ESR). In general, any conventional method for visualizing diagnostic imaging can be utilized. Usually gamma and positron emitting radioisotopes are used for camera imaging and paramagnetic isotopes for MRI. Elements which are particularly useful in such techniques include ^{157}Gd , ^{55}Mn , ^{162}Dy , ^{52}Cr , and ^{56}Fe .

- 28 -

The monoclonal antibodies of the invention can be used *in vitro* and *in vivo* to monitor the course of amelioration of a GDF-9-associated disease in a subject. Thus, for example, by measuring the increase or decrease in the number of cells expressing antigen comprising a polypeptide of the invention or changes in the concentration of such antigen present in various body fluids, it would be possible to determine whether a particular therapeutic regimen aimed at ameliorating the GDF-9-associated disease is effective. The term "ameliorate" denotes a lessening of the detrimental effect of the GDF-9-associated disease in the subject receiving therapy. Similarly, such techniques can be used to follow a contraceptive regime in a subject.

- 10 The present invention identifies a nucleotide sequence that can be expressed in an altered manner as compared to expression in a normal cell, therefore, it is possible to design appropriate therapeutic or diagnostic techniques directed to this sequence. Thus, where a cell-proliferative disorder is associated with the expression of GDF-9, nucleic acid sequences that interfere with GDF-9 expression at the translational level can be used.
- 15 This approach utilizes, for example, antisense nucleic acid and ribozymes to block translation of a specific GDF-9 mRNA, either by masking that mRNA with an antisense nucleic acid or by cleaving it with a ribozyme. In addition, antisense molecules or ribozymes are useful in the contraceptive methods of the invention where it is desirable to inhibit GDF-9 expression. As a further mechanism of action, in "transcription arrest"
- 20 it appears that some polynucleotides can form "triplex," or triple-helical structures with double stranded genomic DNA containing the gene of interest, thus interfering with transcription by RNA polymerase. Giovannangeli *et al.*, *Proc. Natl. Acad. Sci.* **90**:10013 (1993); Ebbinghaus *et al. J. Clin. Invest.* **92**:2433 (1993).

Antisense nucleic acids are DNA or RNA molecules that are complementary to at least a portion of a specific mRNA molecule (Weintraub, *Scientific American*, **262**:40, 1990). In the cell, the antisense nucleic acids hybridize to the corresponding mRNA, forming a double-stranded molecule. The antisense nucleic acids interfere with the translation of the mRNA, since the cell will not translate a mRNA that is double-stranded.

- 29 -

Antisense oligomers of about 15 nucleotides are preferred, since they are easily synthesized and are less likely to cause problems than larger molecules when introduced into the target GDF-9-producing cell. The use of antisense methods to inhibit the *in vitro* translation of genes is well known in the art (Marcus-Sakura, *Anal. Biochem.*, 172:289, 5 1988).

Ribozymes are RNA molecules possessing the ability to specifically cleave other single-stranded RNA in a manner analogous to DNA restriction endonucleases. Through the modification of nucleotide sequences which encode these RNAs, it is possible to engineer molecules that recognize specific nucleotide sequences in an RNA molecule and 10 cleave it (Cech, *J. Amer. Med. Assn.*, 260:3030, 1988). A major advantage of this approach is that, because they are sequence-specific, only mRNAs with particular sequences are inactivated.

There are two basic types of ribozymes namely, *tetrahymena*-type (Hasselhoff, *Nature*, 334:585, 1988) and "hammerhead"-type. *Tetrahymena*-type ribozymes recognize 15 sequences which are four bases in length, while "hammerhead"-type ribozymes recognize base sequences 11-18 bases in length. The longer the recognition sequence, the greater the likelihood that the sequence will occur exclusively in the target mRNA species. Consequently, hammerhead-type ribozymes are preferable to *tetrahymena*-type ribozymes for inactivating a specific mRNA species and 18-based recognition sequences 20 are preferable to shorter recognition sequences.

The present invention also provides gene therapy for the treatment of cell proliferative disorders which are mediated by GDF-9 protein or where it is desirable to inhibit GDF-9 expression for purposes of contraception. Such therapy would achieve its therapeutic effect by introduction of the GDF-9 antisense polynucleotide into cells having the 25 proliferative disorder or introduction of antisense into oocytes. Delivery of antisense or sense GDF-9 polynucleotide, GDF-9 polypeptide or peptides can be achieved using a recombinant expression vector such as a chimeric virus or a colloidal dispersion system.

- 30 -

Especially preferred for therapeutic delivery of antisense sequences is the use of targeted liposomes.

Various viral vectors which can be utilized for gene therapy as taught herein include adenovirus, herpes virus, vaccinia, or, preferably, an RNA virus such as a retrovirus.

- 5 Preferably, the retroviral vector is a derivative of a murine or avian retrovirus. Examples of retroviral vectors in which a single foreign gene can be inserted include, but are not limited to: Moloney murine leukemia virus (MoMuLV), Harvey murine sarcoma virus (HaMuSV), murine mammary tumor virus (MuMTV), and Rous Sarcoma Virus (RSV). A number of additional retroviral vectors can incorporate multiple genes. All of these
- 10 vectors can transfer or incorporate a gene for a selectable marker so that transduced cells can be identified and generated. By inserting a GDF-9 sequence of interest into the viral vector, along with another gene which encodes the ligand for a receptor on a specific target cell, for example, the vector is now target specific. Retroviral vectors can be made target specific by inserting, for example, a polynucleotide encoding a sugar, a glycolipid,
- 15 or a protein. Preferred targeting is accomplished by using an antibody to target the retroviral vector. Those of skill in the art will know of, or can readily ascertain without undue experimentation, specific polynucleotide sequences which can be inserted into the retroviral genome to allow target specific delivery of the retroviral vector containing the GDF-9 antisense polynucleotide.

- 20 Since recombinant retroviruses are defective, they require assistance in order to produce infectious vector particles. This assistance can be provided, for example, by using helper cell lines that contain plasmids encoding all of the structural genes of the retrovirus under the control of regulatory sequences within the LTR. These plasmids are missing a nucleotide sequence which enables the packaging mechanism to recognize an RNA
- 25 transcript for encapsidation. Helper cell lines which have deletions of the packaging signal include, but are not limited to Ψ 2, PA317 and PA12, for example. These cell lines produce empty virions, since no genome is packaged. If a retroviral vector is introduced into such cells in which the packaging signal is intact, but the structural genes are

- 31 -

replaced by other genes of interest, the vector can be packaged and vector virion produced.

Alternatively, NIH 3T3 or other tissue culture cells can be directly transfected with plasmids encoding the retroviral structural genes *gag*, *pol* and *env*, by conventional
5 calcium phosphate transfection. These cells are then transfected with the vector plasmid containing the genes of interest. The resulting cells release the retroviral vector into the culture medium.

Another targeted delivery system for GDF-9 polynucleotides or polypeptides is a colloidal dispersion system. Colloidal dispersion systems include macromolecule
10 complexes, nanocapsules, microspheres, beads, and lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes. The preferred colloidal system of this invention is a liposome. Liposomes are artificial membrane vesicles which are useful as delivery vehicles *in vitro* and *in vivo*. It has been shown that large unilamellar vesicles (LUV), which range in size from 0.2-4.0 μm can encapsulate a
15 substantial percentage of an aqueous buffer containing large macromolecules. RNA, DNA and intact virions can be encapsulated within the aqueous interior and be delivered to cells in a biologically active form (Fraley, *et al.*, *Trends Biochem. Sci.*, 6:77, 1981). In addition to mammalian cells, liposomes have been used for delivery of polynucleotides in plant, yeast and bacterial cells. In order for a liposome to be an
20 efficient gene transfer vehicle, the following characteristics should be present: (1) encapsulation of the genes of interest at high efficiency while not compromising their biological activity; (2) preferential and substantial binding to a target cell in comparison to non-target cells; (3) delivery of the aqueous contents of the vesicle to the target cell cytoplasm at high efficiency; and (4) accurate and effective expression of genetic
25 information (Mannino, *et al.*, *Biotechniques*, 6:682, 1988).

- 32 -

The composition of the liposome is usually a combination of phospholipids, particularly high-phase-transition-temperature phospholipids, usually in combination with steroids, especially cholesterol. Other phospholipids or other lipids may also be used. The physical characteristics of liposomes depend on pH, ionic strength, and the presence of
5 divalent cations.

Examples of lipids useful in liposome production include phosphatidyl compounds, such as phosphatidylglycerol, phosphatidylcholine, phosphatidylserine, phosphatidylethanolamine, sphingolipids, cerebroside, and gangliosides. Particularly useful are diacylphosphatidylglycerols, where the lipid moiety contains from 14-18 carbon atoms,
10 particularly from 16-18 carbon atoms, and is saturated. Illustrative phospholipids include egg phosphatidylcholine, dipalmitoylphosphatidylcholine and distearoylphosphatidylcholine.

The targeting of liposomes can be classified based on anatomical and mechanistic factors. Anatomical classification is based on the level of selectivity, for example, organ-specific, cell-specific, and organelle-specific. Mechanistic targeting can be distinguished
15 based upon whether it is passive or active. Passive targeting utilizes the natural tendency of liposomes to distribute to cells of the reticulo-endothelial system (RES) in organs which contain sinusoidal capillaries. Active targeting, on the other hand, involves alteration of the liposome by coupling the liposome to a specific ligand such as a
20 monoclonal antibody, sugar, glycolipid, or protein, or by changing the composition or size of the liposome in order to achieve targeting to organs and cell types other than the naturally occurring sites of localization.

The surface of the targeted delivery system may be modified in a variety of ways. In the case of a liposomal targeted delivery system, lipid groups can be incorporated into the
25 lipid bilayer of the liposome in order to maintain the targeting ligand in stable association with the liposomal bilayer. Various linking groups can be used for joining the lipid chains to the targeting ligand.

- 33 -

The following examples are intended to illustrate but not limit the invention. While they are typical of those that might be used, other procedures known to those skilled in the art may alternatively be used.

EXAMPLE 1

5 IDENTIFICATION AND ISOLATION OF A NOVEL **TGF- β FAMILY MEMBER**

To identify a new member of the TGF- β superfamily, degenerate oligonucleotides were designed which corresponded to two conserved regions among the known family members: one region spanning the two tryptophan residues conserved in all family
10 members except MIS and the other region spanning the invariant cysteine residues near the C-terminus. These primers were used for polymerase chain reactions on mouse genomic DNA followed by subcloning the PCR products using restriction sites placed at the 5' ends of the primers, picking individual *E. coli* colonies carrying these subcloned inserts, and using a combination of random sequencing and hybridization analysis to
15 eliminate known members of the superfamily.

GDF-9 was identified from a mixture of PCR products obtained with the primers SJL160 (5'-CCGGAATTCGGITGG(G/C/A)A(G/A/T/C)(G/C/A)A(G/A/T/C) TGG(A/G)TI(A/-
G)TI(T/G)CICC-3') and SJL153 (5'-CCGGAATTC(A/G)CAI(G/C)C-(A/G)CAIC(T/C)(G/A/T/C)(C/G/T)TIG(T/C)I(G/A)(T/C)CAT-3'). PCR using these
20 primers was carried out with 2 μ g mouse genomic DNA at 94°C for 1 min, 50°C for 2 min, and 72°C for 2 min for 40 cycles.

PCR products of approximately 280 bp were gel-purified, digested with Eco RI, gel-purified again, and subcloned in the Bluescript vector (Stratagene, San Diego, CA). Bacterial colonies carrying individual subclones were picked into 96 well microtiter
25 plates, and multiple replicas were prepared by plating the cells onto nitrocellulose. The

- 34 -

replicate filters were hybridized to probes representing known members of the family, and DNA was prepared from non-hybridizing colonies for sequence analysis.

The primer combination of SJL160 and SJL153, yielded three known sequences (inhibin β B, BMP-2, and BMP-4) and one novel sequence (designated GDF-9) among 145
5 subclones analyzed.

RNA isolation and Northern analysis were carried out as described previously (Lee, S.J., *Mol. Endocrinol.* 4:1034, 1990). An oligo dT-primed cDNA library was prepared from 2.5-3 μ g of ovary poly A-selected RNA in the lambda ZAP II vector according to the instructions provided by Stratagene. The ovary library was not amplified prior to
10 screening. Filters were hybridized as described previously (Lee, S.-J., *Proc. Natl. Acad. Sci. USA.*, 88:4250-4254, 1991). DNA sequencing of both strands was carried out using the dideoxy chain termination method (Sanger, *et al.*, *Proc. Natl. Acad. Sci., USA.*, 74:5463-5467, 1977) and a combination of the S1 nuclease/exonuclease III strategy (Henikoff, S., *Gene*, 28:351-359, 1984) and synthetic oligonucleotide primers.

15

EXAMPLE 2

EXPRESSION PATTERN AND SEQUENCE OF GDF-9

To determine the expression pattern of GDF-9, RNA samples prepared from a variety of adult tissues were screened by Northern analysis. Five micrograms of twice polyA-selected RNA prepared from each tissue were electrophoresed on formaldehyde gels,
20 blotted and probed with GDF-9. As shown in Figure 1, the GDF-9 probe detected a 1.7 kb mRNA expressed exclusively in the ovary.

A mouse ovary cDNA library of 1.5×10^6 recombinant phage was constructed in lambda ZAP II and screened with a probe derived from the GDF-9 PCR product. The nucleotide sequence of the longest of nineteen hybridizing clones is shown in Figure 2. Consensus
25 N-glycosylation signals are denoted by plain boxes. The putative tetrabasic processing

- 35 -

sites are denoted by stippled boxes. The in-frame termination codons upstream of the putative initiating ATG and the consensus polyadenylation signals are underlined. The poly A tails are not shown. Numbers indicate nucleotide position relative to the 5' end. The 1712 bp sequence contains a long open reading frame beginning with a methionine
 5 codon at nucleotide 29 and potentially encoding a protein 441 amino acids in length with a molecular weight of 49.6 kD. Like other TGF- β family members, the GDF-9 sequence contains a core of hydrophobic amino acids near the N-terminus suggestive of a signal sequence for secretion. GDF-9 contains four potential N-glycosylation sites at asparagine residues 163, 229, 258, and 325 and a putative tetrabasic proteolytic process-
 10 ing site (RRRR) at amino acids 303-306. The mature C-terminal fragment of GDF-9 is predicted to be 135 amino acids in length and have an unglycosylated molecular weight of 15.6 kD. Although the C-terminal portion of GDF-9 clearly shows homology with the other family members, the sequence of GDF-9 is significantly diverged from those of the other family members (Figures 3 and 4). Figure 3 shows the alignment of the C-terminal
 15 sequences of GDF-9 with the corresponding regions of human GDF-1 (Lee, *Proc. Natl. Acad. Sci. USA*, 88:4250-4254, 1991), *Xenopus* Vg-1 (Weeks, *et al.*, *Cell*, 51:861-867, 1987), human Vgr-1 (Celeste, *et al.*, *Proc. Natl. Acad. Sci. USA*, 87:9843-9847, 1990), human OP-1 (Ozkaynak, *et al.*, *EMBO J.*, 9:2085-2093, 1990), human BMP-5 (Celeste, *et al.*, *Proc. Natl. Acad. Sci. USA*, 87:9843-9847, 1990), *Drosophila* 60A (Wharton, *et al.*, *Proc. Natl. Acad. Sci. USA*, 88:9214-9218, 1991), human BMP-2 and 4 (Wozney, *et al.*, *Science*, 242:1528-1534, 1988), *Drosophila* DPP (Padgett, *et al.*, *Nature*, 325:81-84, 1987), human BMP-3 (Wozney, *et al.*, *Science*, 242:1528-1534, 1988), human MIS (Cate, *et al.*, *Cell*, 45:685-698, 1986), human inhibin , β A, and β B (Mason, *et al.*, *Biochem. Biophys. Res. Commun.*, 135:957-964, 1986), human TGF- β 1 (Derynck, *et al.*,
 20 *Nature*, 316:701-705, 1985), human TGF- β 2 (deMartin, *et al.*, *EMBO J.*, 6:3673-3677, 1987), human TGF- β 3 (ten Dijke, *et al.*, *Proc. Natl. Acad. Sci. USA*, 85:4715-4719, 1988), chicken TGF- β 4 (Jakowlew, *et al.*, *Mol. Endocrinol.*, 2:1186-1195, 1988), and *Xenopus* TGF- β 5 (Kondaiah, *et al.*, *J. Biol. Chem.*, 265:1089-1093, 1990). The conserved cysteine residues are shaded. Dashes denote gaps introduced in order to
 25 maximize the alignment.
 30

- 36 -

Figure 4 shows the amino acid homologies among the different members of the TGF- β superfamily. Numbers represent percent amino acid identities between each pair calculated from the first conserved cysteine to the C-terminus. Boxes represent homologies among highly-related members within particular subgroups.

- 5 The degree of sequence identify with known family members ranges from a minimum of 21% with MIS to a maximum of 34% with BMP-4. Hence, GDF-9 is comparable to MIS in its degree of sequence divergence from the other members of this superfamily. Moreover, GDF-9 shows no significant sequence homology to other family members in the pro-region of the molecule. GDF-9 also differs from the known family members in
10 its pattern of cysteine residues in the C-terminal region. GDF-9 lacks the fourth cysteine of the seven cysteines that are present in all other family members; in place of cysteine at this position, the GDF-9 sequence contains a serine residue. In addition, GDF-9 does not contain a seventh cysteine residue elsewhere in the C-terminal region.

EXAMPLE 3

15 IMMUNOCHEMICAL LOCALIZATION OF GDF-9
IN THE ZONA PELLUCIDA

To determine whether GDF-9 mRNA was translated, sections of adult ovaries were incubated with antibodies directed against recombinant GDF-9 protein. In order to raise antibodies against GDF-9, portions of GDF-9 cDNA spanning amino acids 30 to 295
20 (pro-region) or 308 to 441 (mature region) were cloned into the T7-based pET3 expression vector (provided by F.W. Studier, Brookhaven National Laboratory), and the resulting plasmids were transformed into the BL21 (DE3) bacterial strain. Total cell extracts from isopropyl β -D-thiogalactoside-induced cells were electrophoresed on SDS/polyacrylamide gels, and the GDF-9 protein fragments were excised, mixed with
25 Freund's adjuvant, and used to immunize rabbits by standard methods known to those of skill in the art. All immunizations were carried out by Spring Valley Lab (Sykesville, MD). The presence of GDF-9 reactive antibodies in the sera of these rabbits were assessed by Western analysis of bacterially-expressed protein by Western analysis.

- 37 -

For immunohistochemical studies, ovaries were removed from adult mice, fixed in 4% paraformaldehyde, embedded in paraffin, and sectioned. Sites of antibody binding were detected by using the Vectastain ABC kit, according to the instructions provided by Vector Laboratories. FIGURE 5 shows the immunohistochemical localization of GDF-9 protein. Adjacent sections of an adult ovary were either stained with hematoxylin and eosin (FIGURE 5a) or incubated with immune (FIGURE 5b) or pre-immune (FIGURE 5c) serum at a dilution of 1:500. As shown in FIGURE 5b, the antiserum detected protein solely in oocytes. No staining was detected using pre-immune serum (FIGURE 5c). Hence, GDF-9 protein appears to be translated *in vivo* by oocytes.

10

EXAMPLE 4**ISOLATION OF HUMAN GDF-9**

In order to isolate a cDNA clone encoding human GDF-9, a cDNA library was constructed in lambda ZAP II using poly A-selected RNA prepared from an adult human ovary. From this library, a cDNA clone containing the entire human GDF-9 coding sequence was identified using standard screening techniques as in Example 1 and using the murine GDF-9 clone as a probe. A comparison of the predicted amino acid sequences of murine (top lines) and human (bottom lines) GDF-9 is shown in FIGURE 6. Numbers represent amino acid positions relative to the N-termini. Vertical lines represent sequence identities. Dots represent gaps introduced in order to maximize the alignment. The clear box shows the predicted proteolytic processing sites. The shaded boxes show the cysteine residues in the mature region of the proteins. The bars at the bottom show a schematic of the pre-(clear) and mature (shaded) regions of GDF-9 with the percent sequence identities between the murine and human sequences shown below.

Like murine GDF-9, human GDF-9 contains a hydrophobic leader sequence, a putative RXXR proteolytic cleavage site, and a C-terminal region containing the hallmarks of other TGF- β family members. Murine and human GDF-9 are 64% identical in the pro-region and 90% identical in the predicted mature region of the molecule. The high degree

25

- 38 -

of homology between the two sequences suggest that human GDF-9 plays an important role during embryonic development and/or in the adult ovary.

EXAMPLE 5

NUCLEIC ACID DETECTION OF EXPRESSION OF GDF-9 IN OOCYTES

5 In order to localize the expression of GDF-9 in the ovary, *in situ* hybridization to mouse ovary sections was carried out using an antisense GDF-9 RNA probe. FIGURE 7 shows *in situ* hybridization to adult ovary sections using a GDF-9 RNA probe. [³⁵S]-labeled anti-sense (FIGURE 7a and 7c) or sense (FIGURE 7b and 7d) GDF-9 RNA probes were hybridized to adjacent paraffin-embedded sections of ovarians fixed in 4%
10 paraformaldehyde. Sections were dipped in photographic emulsion, exposed, developed, and then stained with hematoxylin and eosin. Two representative fields are shown.

As shown in FIGURES 7a and 7c, GDF-9 mRNA was detected primarily in oocytes in adult ovaries. Every oocyte (regardless of the stage of follicular development) examined showed GDF-9 expression, and no expression was detected in any other cell types. No
15 hybridization was seen using a control GDF-9 sense RNA probe (FIGURE 7b and 7d). Hence, GDF-9 expression appears to be oocyte-specific in adult ovaries.

To determine the pattern of expression of GDF-9 mRNA during ovarian development, sections of neonatal ovaries were probed with a GDF-9 RNA probe. FIGURE 8 shows *in situ* hybridization to a postnatal day 4 ovary section using an antisense GDF-9 RNA
20 probe. Sections were prepared as described for FIGURE 7. Following autoradiography and staining, the section was photographed under bright-field (FIGURE 8a) or dark-field (FIGURE 8b) illumination.

FIGURE 9 shows *in situ* hybridization to postnatal day 8 ovary sections using an antisense (FIGURE 9a) or sense (FIGURE 9b) GDF-9 RNA probe. Sections were
25 prepared as described for FIGURE 7.

- 39 -

GDF-9 mRNA expression was first detected at the onset of follicular development. This was most clearly evident at postnatal day 4, where only oocytes that were present in follicles showed GDF-9 expression (FIGURE 8): no expression was seen in oocytes that were not surrounded by granulosa cells. By postnatal day 8, every oocyte appeared to
5 have undergone follicular development, and every oocyte showed GDF-9 expression (FIGURE 9).

To determine whether GDF-9 was also expressed following ovulation, sections of mouse oviducts were examined by *in situ* hybridization. FIGURE 10 shows *in situ* hybridization to adult oviduct sections using an antisense (FIGURE 10a) or sense
10 (FIGURE 10b) GDF-9 RNA probe. Sections were prepared as described for FIGURE 7.

FIGURE 11 shows *in situ* hybridization to adult oviduct (0.5 days following fertilization) section using an antisense GDF-9 RNA probe. Sections were prepared as described for FIGURE 7. Following autoradiography and staining, the section was photographed
15 under bright-field (FIGURE 11a) or dark-field (FIGURE 11b) illumination.

As shown in FIGURE 10, GDF-9 was expressed by oocytes that had been released into the oviduct. However, the expression of GDF-9 mRNA turned off rapidly following fertilization of the oocytes; by day 0.5 following fertilization, only some embryos (such as the one shown in FIGURE 11) expressed GDF-9 mRNA, and by day 1.5, all embryos
20 were negative for GDF-9 expression.

- 40 -

EXAMPLE 6
CONTRACEPTIVE TARGET

GDF-9 is a novel protein growth factor which regulates the early development and the maturation of the egg (oocyte). Experimental results demonstrate that this factor is essential to the development of the egg. Several lines of evidence support this including:
5 1) GDF-9 mRNA is expressed exclusively by developing and maturing oocytes; 2) GDF-9 protein is secreted by maturing oocytes and is essential for the normal development of the follicle; and 3) GDF-9 deficient (knockout) female mice do not develop mature eggs or follicles and are completely sterile (Dong *et al.*, *Nature*, 383,531, 1996).

10 GDF-9 is a highly specific and novel target for the development of a female contraceptive or as a nonsurgical method of sterilization. There are several different approaches one may use to develop a contraceptive using GDF-9 as a target: 1) the use of the GDF-9 protein or a peptide fragment as a "vaccine"; 2) use of an anti-GDF-9 antibody which binds to and effectively inhibit or neutralize the biological actions of the
15 GDF-9 molecule; and 3) the use of a GDF-9 receptor antagonist. The term "vaccine" as used herein refers to a composition or compound that induces a protective immune response. For example, a GDF-9 "vaccine" protects against conception or pregnancy and acts as a contraceptive.

The following are examples includes different ways that oocyte development and
20 maturation may be regulated in order to prevent ovulation or to cause permanent, nonsurgical sterilization in humans and in other species. These examples are intended to illustrate but not limit the invention. While they are typical of those that might be used, other procedures known to those skilled in the art may alternatively be used.

- 41 -

1. Active Immunization: GDF-9 "vaccines"

The intact GDF-9 protein, or a fragment thereof, is an effective source of the composition used to induce an immune response directed toward oocytes (*e.g.*, vaccine). The intact GDF-9 protein or a monomeric subunit can be economically produced in mammalian cell
5 culture, yeast or microbial culture (such as *Bacillus* or *E. coli*). Alternatively, a peptide fragment of GDF-9 is also a suitable source for producing a vaccine. Typically, such fragments are 10 to 30 amino acids long, are exposed on the exterior portions of the GDF-9 molecule, and may be located within or near the receptor binding portion of the GDF-9 molecule.

10 Several methods can be used to enhance the antigenicity of the GDF-9, or a fragment thereof. Such methods are well known and include forming a chemical complex between a hapten (GDF-9 or a fragment thereof) and a larger carrier molecule (hapten-carrier); mixing the antigen with an adjuvant; or denaturing the protein with heat, detergent, or chaotropic agent (urea or guanidine-HCl).

15 The following experiment can be performed to demonstrate that a GDF-9 composition is an effective contraceptive. Using New Zealand white rabbits as a model, the rabbits are immunized with either the intact GDF-9, a GDF-9 monomer, or one of the GDF-9 fragments listed in the table below. The route of administration is subcutaneous when an adjuvant is used. In the case when an adjuvant is not used, the routes of
20 administration may include subcutaneous, intramuscular, intravenous or intraperitoneal. The preferred route is subcutaneous.

Typically, single or multiple immunization may be required to produce an immune response to GDF-9. The humoral immune response may be monitored by routine serologic methods. Briefly, one to two weeks following the first immunization, a serum
25 sample is obtained and the antibody titer to the GDF-9 protein is determined by either

WO 99/17797

PCT/US98/21199

- 42 -

ELISA or RIA methods. A second or third immunization may be required every 10-14 days in order to produce an effective immune response.

- 43 -

Table 1

GDF-9 vaccines, proteins, concentrations and formulations

	Vaccine	Protein concentration (mg)	Formulation
5	Intact GDF-9 homodimer	0.1, 1.0, 10	neutral buffered saline solution with or without adjuvant ¹
	Heat denatured or chemically denatured GDF-9	0.1, 1.0, 10	neutral buffered saline solution with or without adjuvant
	GDF-9 monomer	0.1, 1.0, 10	neutral buffered saline solution with or without adjuvant
10	GDF-9 monomer conjugated to carrier protein ²	0.1, 1.0, 10	neutral buffered saline solution with or without adjuvant
	GDF-9 fragments 1, 2 or 3 (predicted exposed site within putative receptor binding domain)	0.1, 1.0, 10	neutral buffered saline solution with adjuvant
15	GDF-9 fragments 1, 2 or 3 conjugated to a carrier protein	0.1, 1.0, 10	neutral buffered saline solution with or without adjuvant

¹Adjuvants suitable for use in animals include Freund's complete or incomplete adjuvant. Adjuvants suitable for use in humans will be known to those of skill in the art.

²Monomer is covalently coupled to a suitable carrier protein such as heat denatured immunoglobulin, denatured albumin or KLH.

- 44 -

Rabbits are a good model to demonstrate the effectiveness of a GDF-9 vaccine. Rabbits are immunized with GDF-9 or a GDF-9 fragment in an adjuvant. Antibody titers to GDF-9 are determined in order to assure that a humoral response has been achieved. Gonadotrophin is administered in order to induce ovulation in the rabbit. Following
5 gonadotrophin administration serum progesterone levels are measured. Low serum progesterone levels are an indication that ovulation is inhibited by hyperimmunizing the rabbits with GDF-9 vaccines.

Histologic evaluation of the ovaries from GDF-9 vaccinated rabbits will show that the ovaries are intact. A mild mixed focal inflammatory infiltrate within the medulla of each
10 ovary is observed. The ovaries will be devoid of mature oocytes and follicles. The cortex will appear normal. Histologic examination of the fallopian tubes and uterus will reveal no abnormalities or inflammation.

2. Passive Immunization

Passive immunization is a second approach to developing a GDF-9 specific
15 contraceptive. Using this approach, antibodies are produced which have high affinity of GDF-9. The antibodies are purified by conventional affinity chromatography methods (e.g., protein-A). In this instance, either a immunoglobulin enriched serum fraction (gamma globulin) or a monoclonal antibody generated against GDF-9 is suitable. In these instances, the anti-GDF-9 gamma globulin or the monoclonal antibody will have
20 the property of specifically binding to GDF-9. The antibody may either block the binding of the GDF-9 to its natural receptor or function to increase the rate of clearance of the GDF-9 from the ovary. In either case, the objective is to allow the antibody to contact the GDF-9 produced by the oocytes and prevent it from contacting its natural receptor.

- 45 -

For use in humans, the preferred antibody is a humanized monoclonal antibody. Production of murine monoclonal antibodies is well established and familiar to those skilled in the art. Briefly, mice are immunized with GDF-9 homodimer, monomer or a fragment (Table 1). Once a humoral response is produced, the spleen or lymph node
5 cells are removed and fused with a mouse myeloma cell, typically SP2/0 or P-2 cells. The fused cells (hybridoma) are cultured in a selection media, cloned and subcloned to generate an immortal cell line producing an antibody to GDF-9.

Due to its immunogenicity, the murine monoclonal antibody is not most desirable to use as a therapeutic for human use. The antigenicity of a murine antibody can be reduced by
10 replacing the murine immunoglobulin heavy and light chain constant domains with the equivalent human antibody domains (chimeric antibody). The chimeric antibody can be further "humanized" by replacing intervening structural murine sequences within the antibodies hypervariable regions. This is referred to as a "fully humanized" antibody. The fully humanized antibody is preferred since this antibody can be used repeatedly in
15 a human subject without causing an immune response to the antibody.

3. GDF-9 Receptor Antagonist

A third approach to suppressing GDF-9 function is to develop a receptor antagonist. The approach is to first identify cell surface receptor(s) which are responsible for signal transduction in the ovary. These receptors are likely to be expressed on the egg or
20 associated accessory cells (*e.g.*, granulosa or thecal). Once a target cell population is identified, a receptor binding assay is used to identify peptides or small organic compounds which will bind to the GDF-9 receptor and prevent the GDF-9 from binding to its receptor. The use of the receptor antagonist has the advantage of being a specific inhibitor of GDF-9 induction of oöcyte maturation and the potential to be a long-term,
25 reversible therapeutic.

- 46 -

Although the invention has been described with reference to the presently preferred embodiment, it should be understood that various modifications can be made without departing from the spirit of the invention. Accordingly, the invention is limited only by the following claims.

- 47 -

SUMMARY OF SEQUENCES

Sequence ID No. 1 is the nucleotide sequence for the primer, SJL160, for GDF-9 (page 24, lines 15 and 16);

Sequence ID No. 2 is the nucleotide sequence for the primer, SJL153, for GDF-9 (page 5 24, lines 17 and 18);

Sequence ID No. 3 is the nucleotide and deduced amino acid sequence for GDF-9 (Figure 2);

Sequence ID No. 4 is the deduced amino acid sequence for GDF-9 (Figure 2);

Sequence ID No. 5 is the amino acid sequence of the C-terminus of GDF-3 (Figure 3);

10 Sequence ID No. 6 is the amino acid sequence of the C-terminus of GDF-9 (Figure 3);

Sequence ID No. 7 is the amino acid sequence of the C-terminus of GDF-1 (Figure 3);

Sequence ID No. 8 is the amino acid sequence of the C-terminus of Vg-1 (Figure 3);

Sequence ID No. 9 is the amino acid sequence of the C-terminus of Vgr-1 (Figure 3);

Sequence ID No. 10 is the amino acid sequence of the C-terminus of OP-1 (Figure 3);

15 Sequence ID No. 11 is the amino acid sequence of the C-terminus of BMP-5 (Figure 3);

Sequence ID No. 12 is the amino acid sequence of the C-terminus of 60A (Figure 3);

Sequence ID No. 13 is the amino acid sequence of the C-terminus of BMP-2 (Figure 3);

- 48 -

Sequence ID No. 14 is the amino acid sequence of the C-terminus of BMP-4 (Figure 3);

Sequence ID No. 15 is the amino acid sequence of the C-terminus of DPP (Figure 3);

Sequence ID No. 16 is the amino acid sequence of the C-terminus of BMP-3 (Figure 3);

Sequence ID No. 17 is the amino acid sequence of the C-terminus of MIS (Figure 3);

5 Sequence ID No. 18 is the amino acid sequence of the C-terminus of inhibin (Figure 3);

Sequence ID No. 19 is the amino acid sequence of the C-terminus of β A (Figure 3);

Sequence ID No. 20 is the amino acid sequence of the C-terminus of β B (Figure 3);

Sequence ID No. 21 is the amino acid sequence of the C-terminus of TGF- β 1 (Figure 3);

Sequence ID No. 22 is the amino acid sequence of the C-terminus of TGF- β 2 (Figure 3);

10 Sequence ID No. 23 is the amino acid sequence of the C-terminus of TGF- β 3 (Figure 3);

Sequence ID No. 24 is the amino acid sequence of the C-terminus of TGF- β 4 (Figure 3);

Sequence ID No. 25 is the amino acid sequence of the C-terminus of TGF- β 5 (Figure 3);

and

Sequence ID No. 26 is the amino acid sequence of the C-terminus of GDF-9 (Figure 6).

--SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (I) APPLICANT: The Johns Hopkins University School of Medicine
- (ii) TITLE OF INVENTION: GROWTH DIFFERENTIATION FACTOR-9
- (iii) NUMBER OF SEQUENCES: 26
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Fish & Richardson
 - (B) STREET: 4225 Executive Square, Suite 1400
 - (C) CITY: San Diego
 - (D) STATE: California
 - (E) COUNTRY: USA
 - (F) ZIP: 92037
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: US 08/946,092
 - (B) FILING DATE: 06-OCT-1997
 - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: US 08/491,835
 - (B) FILING DATE: 23-OCT-1995
 - (C) CLASSIFICATION:
- (vi) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: PCT/US94/00685
 - (B) FILING DATE: 12-JAN-1994
 - (C) CLASSIFICATION:
- (vi) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: US 08/003,303
 - (B) FILING DATE: 12-JAN-1993
 - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Lisa A. Haile Ph.D., J.D.
 - (B) REGISTRATION NUMBER: 38,347
 - (C) REFERENCE/DOCKET NUMBER: 07265/138WO1
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: (619) 678-5070
 - (B) TELEFAX: (619) 678-5099

(2) INFORMATION FOR SEQ ID NO:1:

- (I) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 35 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)

WO 99/17797

2

PCT/US98/21199

(vii) IMMEDIATE SOURCE:
(B) CLONE: SJL160

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 1..35
(D) OTHER INFORMATION: /note= "Where "B" occurs, B =
inosine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

CCGGAATTCTG GBTGGVANVA NTGGRTBRTB KCBCC

35

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vii) IMMEDIATE SOURCE:
(B) CLONE: SJL153

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 1..33

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

CCGGAATTCR CADSCRCADC YNBTDGYDRY CAT

33

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1712 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vii) IMMEDIATE SOURCE:
(B) CLONE: GDF-9

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 29..1351

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

ATGCGTTCCT TCTTAGTTCT TCCAAGTC ATG GCA CTT CCC AGC AAC TTC CTG
Met Ala Leu Pro Ser Asn Phe Leu
1 5

52

WO 99/17797

PCT/US98/21199

3

TTG	GGG	GTT	TGC	TGC	TTT	GCC	TGG	CTG	TGT	TTT	CTT	AGT	AGC	CTT	AGC	100
Leu	Gly	Val	Cys	Cys	Phe	Ala	Trp	Leu	Cys	Phe	Leu	Ser	Ser	Leu	Ser	
	10					15					20					
TCT	CAG	GCT	TCT	ACT	GAA	GAA	TCC	CAG	AGT	GGA	GCC	AGT	GAA	AAT	GTG	148
Ser	Gln	Ala	Ser	Thr	Glu	Glu	Ser	Gln	Ser	Gly	Ala	Ser	Glu	Asn	Val	
25					30					35					40	
GAG	TCT	GAG	GCA	GAC	CCC	TGG	TCC	TTG	CTG	CTG	CCT	GTA	GAT	GGG	ACT	196
Glu	Ser	Glu	Ala	Asp	Pro	Trp	Ser	Leu	Leu	Leu	Pro	Val	Asp	Gly	Thr	
				45					50					55		
GAC	AGG	TCT	GGC	CTC	TTG	CCC	CCC	CTC	TTT	AAG	GTT	CTA	TCT	GAT	AGG	244
Asp	Arg	Ser	Gly	Leu	Leu	Pro	Pro	Leu	Phe	Lys	Val	Leu	Ser	Asp	Arg	
			60					65					70			
CGA	GGT	GAG	ACC	CCT	AAG	CTG	CAG	CCT	GAC	TCC	AGA	GCA	CTC	TAC	TAC	292
Arg	Gly	Glu	Thr	Pro	Lys	Leu	Gln	Pro	Asp	Ser	Arg	Ala	Leu	Tyr	Tyr	
		75					80					85				
ATG	AAA	AAG	CTC	TAT	AAG	ACG	TAT	GCT	ACC	AAA	GAG	GGG	GTT	CCC	AAA	340
Met	Lys	Lys	Leu	Tyr	Lys	Thr	Tyr	Ala	Thr	Lys	Glu	Gly	Val	Pro	Lys	
	90					95					100					
CCC	AGC	AGA	AGT	CAC	CTC	TAC	AAT	ACC	GTC	CGG	CTC	TTC	AGT	CCC	TGT	388
Pro	Ser	Arg	Ser	His	Leu	Tyr	Asn	Thr	Val	Arg	Leu	Phe	Ser	Pro	Cys	
105					110					115					120	
GCC	CAG	CAA	GAG	CAG	GCA	CCC	AGC	AAC	CAG	GTG	ACA	GGA	CCG	CTG	CCG	436
Ala	Gln	Gln	Glu	Gln	Ala	Pro	Ser	Asn	Gln	Val	Thr	Gly	Pro	Leu	Pro	
				125					130					135		
ATG	GTG	GAC	CTG	CTG	TTT	AAC	CTG	GAC	CGG	GTG	ACT	GCC	ATG	GAA	CAC	484
Met	Val	Asp	Leu	Leu	Phe	Asn	Leu	Asp	Arg	Val	Thr	Ala	Met	Glu	His	
			140					145					150			
TTG	CTC	AAA	TCG	GTC	TTG	CTA	TAC	ACT	CTG	AAC	AAC	TCT	GCC	TCT	TCC	532
Leu	Leu	Lys	Ser	Val	Leu	Leu	Tyr	Thr	Leu	Asn	Asn	Ser	Ala	Ser	Ser	
		155					160					165				
TCC	TCC	ACT	GTG	ACC	TGT	ATG	TGT	GAC	CTT	GTG	GTA	AAG	GAG	GCC	ATG	580
Ser	Ser	Thr	Val	Thr	Cys	Met	Cys	Asp	Leu	Val	Val	Lys	Glu	Ala	Met	
	170					175					180					
TCT	TCT	GGC	AGG	GCA	CCC	CCA	AGA	GCA	CCG	TAC	TCA	TTC	ACC	CTG	AAG	628
Ser	Ser	Gly	Arg	Ala	Pro	Pro	Arg	Ala	Pro	Tyr	Ser	Phe	Thr	Leu	Lys	
185					190					195					200	
AAA	CAC	AGA	TGG	ATT	GAG	ATT	GAT	GTG	ACC	TCC	CTC	CTT	CAG	CCC	CTA	676
Lys	His	Arg	Trp	Ile	Glu	Ile	Asp	Val	Thr	Ser	Leu	Leu	Gln	Pro	Leu	
				205					210					215		
GTG	ACC	TCC	AGC	GAG	AGG	AGC	ATT	CAC	CTG	TCT	GTC	AAT	TTT	ACA	TGC	724
Val	Thr	Ser	Ser	Glu	Arg	Ser	Ile	His	Leu	Ser	Val	Asn	Phe	Thr	Cys	
			220					225					230			
ACA	AAA	GAC	CAG	GTG	CCA	GAG	GAC	GGA	GTG	TTT	AGC	ATG	CCT	CTC	TCA	772
Thr	Lys	Asp	Gln	Val	Pro	Glu	Asp	Gly	Val	Phe	Ser	Met	Pro	Leu	Ser	
		235					240					245				

GTG Val	CCT Pro	CCT Pro	TCC Ser	CTC Leu	ATC Ile	TTG Leu	TAT Tyr	CTC Leu	AAC Asn	GAC Asp	ACA Thr	AGC Ser	ACC Thr	CAG Gln	GCC Ala	820
250						255					260					
TAC Tyr	CAC His	TCT Ser	TGG Trp	CAG Gln	TCT Ser	CTT Leu	CAG Gln	TCC Ser	ACC Thr	TGG Trp	AGG Arg	CCT Pro	TTA Leu	CAG Gln	CAT His	868
265					270					275					280	
CCC Pro	GGC Gly	CAG Gln	GCC Ala	GGT Gly	GTG Val	GCT Ala	GCC Ala	CGT Arg	CCC Pro	GTG Val	AAA Lys	GAG Glu	GAA Glu	GCT Ala	ACT Thr	916
				285					290					295		
GAG Glu	GTG Val	GAA Glu	AGA Arg	TCT Ser	CCC Pro	CGG Arg	CGC Arg	CGT Arg	CGA Arg	GGG Gly	CAG Gln	AAA Lys	GCC Ala	ATC Ile	CGC Arg	964
			300					305					310			
TCC Ser	GAA Glu	GCG Ala	AAG Lys	GGG Gly	CCA Pro	CTT Leu	CTT Leu	ACA Thr	GCA Ala	TCC Ser	TTC Phe	AAC Asn	CTC Leu	AGC Ser	GAA Glu	1012
		315					320					325				
TAC Tyr	TTC Phe	AAA Lys	CAG Gln	TTT Phe	CTT Leu	TTC Phe	CCC Pro	CAA Gln	AAC Asn	GAG Glu	TGT Cys	GAA Glu	CTC Leu	CAT His	GAC Asp	1060
	330					335					340					
TTC Phe	AGA Arg	CTG Leu	AGT Ser	TTT Phe	AGT Ser	CAG Gln	CTC Leu	AAA Lys	TGG Trp	GAC Asp	AAC Asn	TGG Trp	ATC Ile	GTG Val	GCC Ala	1108
345					350					355					360	
CCG Pro	CAC His	AGG Arg	TAC Tyr	AAC Asn	CCT Pro	AGG Arg	TAC Tyr	TGT Cys	AAA Lys	GGG Gly	GAC Asp	TGT Cys	CCT Pro	AGG Arg	GCG Ala	1156
				365					370					375		
GTC Val	AGG Arg	CAT His	CGG Arg	TAT Tyr	GGC Gly	TCT Ser	CCT Pro	GTG Val	CAC His	ACC Thr	ATG Met	GTC Val	CAG Gln	AAT Asn	ATA Ile	1204
			380					385					390			
ATC Ile	TAT Tyr	GAG Glu	AAG Lys	CTG Leu	GAC Asp	CCT Pro	TCA Ser	GTG Val	CCA Pro	AGG Arg	CCT Pro	TCG Ser	TGT Cys	GTG Val	CCG Pro	1252
		395				400						405				
GGC Gly	AAG Lys	TAC Tyr	AGC Ser	CCC Pro	CTG Leu	AGT Ser	GTG Val	TTG Leu	ACC Thr	ATT Ile	GAA Glu	CCC Pro	GAC Asp	GGC Gly	TCC Ser	1300
	410					415					420					
ATC Ile	GCT Ala	TAC Tyr	AAA Lys	GAG Glu	TAC Tyr	GAA Glu	GAC Asp	ATG Met	ATA Ile	GCT Ala	ACG Thr	AGG Arg	TGC Cys	ACC Thr	TGT Cys	1348
425					430					435					440	
CGT Arg	TAGCATGGGG GCCACTTCAA CAAGCCTGCC TGGCAGAGCA ATGCTGTGGG															1401

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 441 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

```

Met Ala Leu Pro Ser Asn Phe Leu Leu Gly Val Cys Cys Phe Ala Trp
1           5           10           15
Leu Cys Phe Leu Ser Ser Leu Ser Ser Gln Ala Ser Thr Glu Glu Ser
20           25           30
Gln Ser Gly Ala Ser Glu Asn Val Glu Ser Glu Ala Asp Pro Trp Ser
35           40           45
Leu Leu Leu Pro Val Asp Gly Thr Asp Arg Ser Gly Leu Leu Pro Pro
50           55           60
Leu Phe Lys Val Leu Ser Asp Arg Arg Gly Glu Thr Pro Lys Leu Gln
65           70           75           80
Pro Asp Ser Arg Ala Leu Tyr Tyr Met Lys Lys Leu Tyr Lys Thr Tyr
85           90           95
Ala Thr Lys Glu Gly Val Pro Lys Pro Ser Arg Ser His Leu Tyr Asn
100          105          110
Thr Val Arg Leu Phe Ser Pro Cys Ala Gln Gln Glu Gln Ala Pro Ser
115          120          125
Asn Gln Val Thr Gly Pro Leu Pro Met Val Asp Leu Leu Phe Asn Leu
130          135          140
Asp Arg Val Thr Ala Met Glu His Leu Leu Lys Ser Val Leu Leu Tyr
145          150          155          160
Thr Leu Asn Asn Ser Ala Ser Ser Ser Ser Thr Val Thr Cys Met Cys
165          170          175
Asp Leu Val Val Lys Glu Ala Met Ser Ser Gly Arg Ala Pro Pro Arg
180          185          190
Ala Pro Tyr Ser Phe Thr Leu Lys Lys His Arg Trp Ile Glu Ile Asp
195          200          205
Val Thr Ser Leu Leu Gln Pro Leu Val Thr Ser Ser Glu Arg Ser Ile
210          215          220
His Leu Ser Val Asn Phe Thr Cys Thr Lys Asp Gln Val Pro Glu Asp
225          230          235          240
Gly Val Phe Ser Met Pro Leu Ser Val Pro Pro Ser Leu Ile Leu Tyr
245          250          255
Leu Asn Asp Thr Ser Thr Gln Ala Tyr His Ser Trp Gln Ser Leu Gln
260          265          270

```

WO 99/17797

PCT/US98/21199

6

Ser Thr Trp Arg Pro Leu Gln His Pro Gly Gln Ala Gly Val Ala Ala
 275 280 285
 Arg Pro Val Lys Glu Glu Ala Thr Glu Val Glu Arg Ser Pro Arg Arg
 290 295 300
 Arg Arg Gly Gln Lys Ala Ile Arg Ser Glu Ala Lys Gly Pro Leu Leu
 305 310 315 320
 Thr Ala Ser Phe Asn Leu Ser Glu Tyr Phe Lys Gln Phe Leu Phe Pro
 325 330 335
 Gln Asn Glu Cys Glu Leu His Asp Phe Arg Leu Ser Phe Ser Gln Leu
 340 345 350
 Lys Trp Asp Asn Trp Ile Val Ala Pro His Arg Tyr Asn Pro Arg Tyr
 355 360 365
 Cys Lys Gly Asp Cys Pro Arg Ala Val Arg His Arg Tyr Gly Ser Pro
 370 375 380
 Val His Thr Met Val Gln Asn Ile Ile Tyr Glu Lys Leu Asp Pro Ser
 385 390 395 400
 Val Pro Arg Pro Ser Cys Val Pro Gly Lys Tyr Ser Pro Leu Ser Val
 405 410 415
 Leu Thr Ile Glu Pro Asp Gly Ser Ile Ala Tyr Lys Glu Tyr Glu Asp
 420 425 430
 Met Ile Ala Thr Arg Cys Thr Cys Arg
 435 440

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 117 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(vii) IMMEDIATE SOURCE:

- (B) CLONE: GDF-3

(ix) FEATURE:

- (A) NAME/KEY: Protein
- (B) LOCATION: 1..117

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Lys Arg Arg Ala Ala Ile Ser Val Pro Lys Gly Phe Cys Arg Asn Phe
 1 5 10 15
 Cys His Arg His Gln Leu Phe Ile Asn Phe Gln Asp Leu Gly Trp His
 20 25 30
 Lys Trp Val Ile Ala Pro Lys Gly Phe Met Ala Asn Tyr Cys His Gly
 35 40 45

WO 99/17797

PCT/US98/21199

7

Glu Cys Pro Phe Ser Met Thr Thr Tyr Leu Asn Ser Ser Asn Tyr Ala
 50 55 60
 Phe Met Gln Ala Leu Met His Met Ala Asp Pro Lys Val Pro Lys Ala
 65 70 75 80
 Val Cys Val Pro Thr Lys Leu Ser Pro Ile Ser Met Leu Tyr Gln Asp
 85 90 95
 Ser Asp Lys Asn Val Ile Leu Arg His Tyr Glu Asp Met Val Val Asp
 100 105 110
 Glu Cys Gly Cys Gly
 115

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 118 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(vii) IMMEDIATE SOURCE:

- (B) CLONE: GDF-9

(ix) FEATURE:

- (A) NAME/KEY: Protein
- (B) LOCATION: 1..118

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Phe Asn Leu Ser Glu Tyr Phe Lys Gln Phe Leu Phe Pro Gln Asn Glu
 1 5 10 15
 Cys Glu Leu His Asp Phe Arg Leu Ser Phe Ser Gln Leu Lys Trp Asp
 20 25 30
 Asn Trp Ile Val Ala Pro His Arg Tyr Asn Pro Arg Tyr Cys Lys Gly
 35 40 45
 Asp Cys Pro Arg Ala Val Arg His Arg Tyr Gly Ser Pro Val His Thr
 50 55 60
 Met Val Gln Asn Ile Ile Tyr Glu Lys Leu Asp Pro Ser Val Pro Arg
 65 70 75 80
 Pro Ser Cys Val Pro Gly Lys Tyr Ser Pro Leu Ser Val Leu Thr Ile
 85 90 95
 Glu Pro Asp Gly Ser Ile Ala Tyr Lys Glu Tyr Glu Asp Met Ile Ala
 100 105 110
 Thr Arg Cys Thr Cys Arg
 115

(2) INFORMATION FOR SEQ ID NO:7:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 122 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(vii) IMMEDIATE SOURCE:
 (B) CLONE: GDF-1

(ix) FEATURE:
 (A) NAME/KEY: Protein
 (B) LOCATION: 1..122

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

```

Pro Arg Arg Asp Ala Glu Pro Val Leu Gly Gly Gly Pro Gly Gly Ala
1           5           10           15
Cys Arg Ala Arg Arg Leu Tyr Val Ser Phe Arg Glu Val Gly Trp His
                20           25           30
Arg Trp Val Ile Ala Pro Arg Gly Phe Leu Ala Asn Tyr Cys Gln Gly
                35           40           45
Gln Cys Ala Leu Pro Val Ala Leu Ser Gly Ser Gly Gly Pro Pro Ala
                50           55           60
Leu Asn His Ala Val Leu Arg Ala Leu Met His Ala Ala Ala Pro Gly
65           70           75           80
Ala Ala Asp Leu Pro Cys Cys Val Pro Ala Arg Leu Ser Pro Ile Ser
                85           90           95
Val Leu Phe Phe Asp Asn Ser Asp Asn Val Val Leu Arg Gln Tyr Glu
                100          105          110
Asp Met Val Val Asp Glu Cys Gly Cys Arg
                115          120

```

(2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 118 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(vii) IMMEDIATE SOURCE:
 (B) CLONE: Vg-1

(ix) FEATURE:
 (A) NAME/KEY: Protein
 (B) LOCATION: 1..118

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

```

Arg Arg Lys Arg Ser Tyr Ser Lys Leu Pro Phe Thr Ala Ser Asn Ile
1          5          10          15
Cys Lys Lys Arg His Leu Tyr Val Glu Phe Lys Asp Val Gly Trp Gln
          20          25          30
Asn Trp Val Ile Ala Pro Gln Gly Tyr Met Ala Asn Tyr Cys Tyr Gly
          35          40          45
Glu Cys Pro Tyr Pro Leu Thr Glu Ile Leu Asn Gly Ser Asn His Ala
          50          55          60
Ile Leu Gln Thr Leu Val His Ser Ile Glu Pro Glu Asp Ile Pro Leu
65          70          75          80
Pro Cys Cys Val Pro Thr Lys Met Ser Pro Ile Ser Met Leu Phe Tyr
          85          90          95
Asp Asn Asn Asp Asn Val Val Leu Arg His Tyr Glu Asn Met Ala Val
          100          105          110
Asp Glu Cys Gly Cys Arg
          115

```

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 118 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(vii) IMMEDIATE SOURCE:

- (B) CLONE: Vgr-1

(ix) FEATURE:

- (A) NAME/KEY: Protein
- (B) LOCATION: 1..118

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

```

Arg Val Ser Ser Ala Ser Asp Tyr Asn Ser Ser Glu Leu Lys Thr Ala
1          5          10          15
Cys Arg Lys His Glu Leu Tyr Val Ser Phe Gln Asp Leu Gly Trp Gln
          20          25          30
Asp Trp Ile Ile Ala Pro Lys Gly Tyr Ala Ala Asn Tyr Cys Asp Gly
          35          40          45
Glu Cys Ser Phe Pro Leu Asn Ala His Met Asn Ala Thr Asn His Ala
          50          55          60
Ile Val Gln Thr Leu Val His Leu Met Asn Pro Glu Tyr Val Pro Lys
65          70          75          80

```

WO 99/17797

PCT/US98/21199

10

Pro Cys Cys Ala Pro Thr Lys Leu Asn Ala Ile Ser Val Leu Tyr Phe
 85 90 95

Asp Asp Asn Ser Asn Val Ile Leu Lys Lys Tyr Arg Asn Met Val Val
 100 105 110

Arg Ala Cys Gly Cys His
 115

(2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 118 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(vii) IMMEDIATE SOURCE:
 (B) CLONE: OP-1

(ix) FEATURE:
 (A) NAME/KEY: Protein
 (B) LOCATION: 1..118

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Arg Met Ala Asn Val Ala Glu Asn Ser Ser Ser Asp Gln Arg Gln Ala
 1 5 10 15

Cys Lys Lys His Glu Leu Tyr Val Ser Phe Arg Asp Leu Gly Trp Gln
 20 25 30

Asp Trp Ile Ile Ala Pro Glu Gly Tyr Ala Ala Tyr Tyr Cys Glu Gly
 35 40 45

Glu Cys Ala Phe Pro Leu Asn Ser Tyr Met Asn Ala Thr Asn His Ala
 50 55 60

Ile Val Gln Thr Leu Val His Phe Ile Asn Pro Glu Thr Val Pro Lys
 65 70 75 80

Pro Cys Cys Ala Pro Thr Gln Leu Asn Ala Ile Ser Val Leu Tyr Phe
 85 90 95

Asp Asp Ser Ser Asn Val Ile Leu Lys Lys Tyr Arg Asn Met Val Val
 100 105 110

Arg Ala Cys Gly Cys His
 115

(2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 118 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

WO 99/17797

PCT/US98/21199

11

(ii) MOLECULE TYPE: protein

(vii) IMMEDIATE SOURCE:

(B) CLONE: BMP-5

(ix) FEATURE:

(A) NAME/KEY: Protein

(B) LOCATION: 1..118

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

```

Arg Met Ser Ser Val Gly Asp Tyr Asn Thr Ser Glu Gln Lys Gln Ala
1           5           10           15
Cys Lys Lys His Glu Leu Tyr Val Ser Phe Arg Asp Leu Gly Trp Gln
                20           25           30
Asp Trp Ile Ile Ala Pro Glu Gly Tyr Ala Ala Phe Tyr Cys Asp Gly
                35           40           45
Glu Cys Ser Phe Pro Leu Asn Ala His Met Asn Ala Thr Asn His Ala
        50           55           60
Ile Val Gln Thr Leu Val His Leu Met Phe Pro Asp His Val Pro Lys
65           70           75           80
Pro Cys Cys Ala Pro Thr Lys Leu Asn Ala Ile Ser Val Leu Tyr Phe
                85           90           95
Asp Asp Ser Ser Asn Val Ile Leu Lys Lys Tyr Arg Asn Met Val Val
                100           105           110
Arg Ser Cys Gly Cys His
                115

```

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 118 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(vii) IMMEDIATE SOURCE:

(B) CLONE: 60A

(ix) FEATURE:

(A) NAME/KEY: Protein

(B) LOCATION: 1..118

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

```

Ser Pro Asn Asn Val Pro Leu Leu Glu Pro Met Glu Ser Thr Arg Ser
1           5           10           15
Cys Gln Met Gln Thr Leu Tyr Ile Asp Phe Lys Asp Leu Gly Trp His
                20           25           30

```

WO 99/17797

PCT/US98/21199

12

Asp Trp Ile Ile Ala Pro Glu Gly Tyr Gly Ala Phe Tyr Cys Ser Gly
 35 40 45
 Glu Cys Asn Phe Pro Leu Asn Ala His Met Asn Ala Thr Asn His Ala
 50 55 60
 Ile Val Gln Thr Leu Val His Leu Leu Glu Pro Lys Lys Val Pro Lys
 65 70 75 80
 Pro Cys Cys Ala Pro Thr Arg Leu Gly Ala Leu Pro Val Leu Tyr His
 85 90 95
 Leu Asn Asp Glu Asn Val Asn Leu Lys Lys Tyr Arg Asn Met Ile Val
 100 105 110
 Lys Ser Cys Gly Cys His
 115

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 117 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(vii) IMMEDIATE SOURCE:

- (B) CLONE: BMP-2

(ix) FEATURE:

- (A) NAME/KEY: Protein
- (B) LOCATION: 1..117

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

Glu Lys Arg Gln Ala Lys His Lys Gln Arg Lys Arg Leu Lys Ser Ser
 1 5 10 15
 Cys Lys Arg His Pro Leu Tyr Val Asp Phe Ser Asp Val Gly Trp Asn
 20 25 30
 Asp Trp Ile Val Ala Pro Pro Gly Tyr His Ala Phe Tyr Cys His Gly
 35 40 45
 Glu Cys Pro Phe Pro Leu Ala Asp His Leu Asn Ser Thr Asn His Ala
 50 55 60
 Ile Val Gln Thr Leu Val Asn Ser Val Asn Ser Lys Ile Pro Lys Ala
 65 70 75 80
 Cys Cys Val Pro Thr Glu Leu Ser Ala Ile Ser Met Leu Tyr Leu Asp
 85 90 95
 Glu Asn Glu Lys Val Val Leu Lys Asn Tyr Gln Asp Met Val Val Glu
 100 105 110
 Gly Cys Gly Cys Arg
 115

(2) INFORMATION FOR SEQ ID NO:14:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 117 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(vii) IMMEDIATE SOURCE:
 (B) CLONE: BMP-4

(ix) FEATURE:
 (A) NAME/KEY: Protein
 (B) LOCATION: 1..117

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

Arg	Ser	Pro	Lys	His	His	Ser	Gln	Arg	Ala	Arg	Lys	Lys	Asn	Lys	Asn	1	5	10	15
Cys	Arg	Arg	His	Ser	Leu	Tyr	Val	Asp	Phe	Ser	Asp	Val	Gly	Trp	Asn	20	25	30	
Asp	Trp	Ile	Val	Ala	Pro	Pro	Gly	Tyr	Gln	Ala	Phe	Tyr	Cys	His	Gly	35	40	45	
Asp	Cys	Pro	Phe	Pro	Leu	Ala	Asp	His	Leu	Asn	Ser	Thr	Asn	His	Ala	50	55	60	
Ile	Val	Gln	Thr	Leu	Val	Asn	Ser	Val	Asn	Ser	Ser	Ile	Pro	Lys	Ala	65	70	75	80
Cys	Cys	Val	Pro	Thr	Glu	Leu	Ser	Ala	Ile	Ser	Met	Leu	Tyr	Leu	Asp	85	90	95	
Glu	Tyr	Asp	Lys	Val	Val	Leu	Lys	Asn	Tyr	Gln	Glu	Met	Val	Val	Glu	100	105	110	
Gly	Cys	Gly	Cys	Arg												115			

(2) INFORMATION FOR SEQ ID NO:15:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 118 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(vii) IMMEDIATE SOURCE:
 (B) CLONE: DPP

(ix) FEATURE:
 (A) NAME/KEY: Protein
 (B) LOCATION: 1..118

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

Lys Arg His Ala Arg Arg Pro Thr Arg Arg Lys Asn His Asp Asp Thr
 1 5 10 15
 Cys Arg Arg His Ser Leu Tyr Val Asp Phe Ser Asp Val Gly Trp Asp
 20 25 30
 Asp Trp Ile Val Ala Pro Leu Gly Tyr Asp Ala Tyr Tyr Cys His Gly
 35 40 45
 Lys Cys Pro Phe Pro Leu Ala Asp His Phe Asn Ser Thr Asn His Ala
 50 55 60
 Val Val Gln Thr Leu Val Asn Asn Met Asn Pro Gly Lys Val Pro Lys
 65 70 75 80
 Ala Cys Cys Val Pro Thr Gln Leu Asp Ser Val Ala Met Leu Tyr Leu
 85 90 95
 Asn Asp Gln Ser Thr Val Val Leu Lys Asn Tyr Gln Glu Met Thr Val
 100 105 110
 Val Gly Cys Gly Cys Arg
 115

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 119 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(vii) IMMEDIATE SOURCE:

- (B) CLONE: BMP-3

(ix) FEATURE:

- (A) NAME/KEY: Protein
- (B) LOCATION: 1..119

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

Gln Thr Leu Lys Lys Ala Arg Arg Lys Gln Trp Ile Glu Pro Arg Asn
 1 5 10 15
 Cys Ala Arg Arg Tyr Leu Lys Val Asp Phe Ala Asp Ile Gly Trp Ser
 20 25 30
 Glu Trp Ile Ile Ser Pro Lys Ser Phe Asp Ala Tyr Tyr Cys Ser Gly
 35 40 45
 Ala Cys Gln Phe Pro Met Pro Lys Ser Leu Lys Pro Ser Asn His Ala
 50 55 60
 Thr Ile Gln Ser Ile Val Arg Ala Val Gly Val Val Pro Gly Ile Pro
 65 70 75 80

WO 99/17797

15

PCT/US98/21199

Glu Pro Cys Cys Val Pro Glu Lys Met Ser Ser Leu Ser Ile Leu Phe
 85 90 95

Phe Asp Glu Asn Lys Asn Val Val Leu Lys Val Tyr Pro Asn Met Thr
 100 105 110

Val Glu Ser Cys Ala Cys Arg
 115

(2) INFORMATION FOR SEQ ID NO:17:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 115 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(vii) IMMEDIATE SOURCE:
 (B) CLONE: MIS

(ix) FEATURE:
 (A) NAME/KEY: Protein
 (B) LOCATION: 1..115

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

Pro Gly Arg Ala Gln Arg Ser Ala Gly Ala Thr Ala Ala Asp Gly Pro
 1 5 10 15

Cys Ala Leu Arg Glu Leu Ser Val Asp Leu Arg Ala Glu Arg Ser Val
 20 25 30

Leu Ile Pro Glu Thr Tyr Gln Ala Asn Asn Cys Gln Gly Val Cys Gly
 35 40 45

Trp Pro Gln Ser Asp Arg Asn Pro Arg Tyr Gly Asn His Val Val Leu
 50 55 60

Leu Leu Lys Met Gln Ala Arg Gly Ala Ala Leu Ala Arg Pro Pro Cys
 65 70 75 80

Cys Val Pro Thr Ala Tyr Ala Gly Lys Leu Leu Ile Ser Leu Ser Glu
 85 90 95

Glu Arg Ile Ser Ala His His Val Pro Asn Met Val Ala Thr Glu Cys
 100 105 110

Gly Cys Arg
 115

(2) INFORMATION FOR SEQ ID NO:18:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 121 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

WO 99/17797

PCT/US98/21199

16

(vii) IMMEDIATE SOURCE:
(B) CLONE: Inhibin alpha

(ix) FEATURE:
(A) NAME/KEY: Protein
(B) LOCATION: 1..121

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

```

Leu Arg Leu Leu Gln Arg Pro Pro Glu Glu Pro Ala Ala His Ala Asn
1          5          10          15
Cys His Arg Val Ala Leu Asn Ile Ser Phe Gln Glu Leu Gly Trp Glu
          20          25          30
Arg Trp Ile Val Tyr Pro Pro Ser Phe Ile Phe His Tyr Cys His Gly
          35          40          45
Gly Cys Gly Leu His Ile Pro Pro Asn Leu Ser Leu Pro Val Pro Gly
50          55          60
Ala Pro Pro Thr Pro Ala Gln Pro Tyr Ser Leu Leu Pro Gly Ala Gln
65          70          75          80
Pro Cys Cys Ala Ala Leu Pro Gly Thr Met Arg Pro Leu His Val Arg
          85          90          95
Thr Thr Ser Asp Gly Gly Tyr Ser Phe Lys Tyr Glu Thr Val Pro Asn
          100          105          110
Leu Leu Thr Gln His Cys Ala Cys Ile
          115          120

```

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 121 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(vii) IMMEDIATE SOURCE:
(B) CLONE: Inhibin betaA

(ix) FEATURE:
(A) NAME/KEY: Protein
(B) LOCATION: 1..121

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

```

Arg Arg Arg Arg Arg Gly Leu Glu Cys Asp Gly Lys Val Asn Ile Cys
1          5          10          15
Cys Lys Lys Gln Phe Phe Val Ser Phe Lys Asp Ile Gly Trp Asn Asp
          20          25          30

```

WO 99/17797

PCT/US98/21199

17

Trp Ile Ile Ala Pro Ser Gly Tyr His Ala Asn Tyr Cys Glu Gly Glu
 35 40 45
 Cys Pro Ser His Ile Ala Gly Thr Ser Gly Ser Ser Leu Ser Phe His
 50 55 60
 Ser Thr Val Ile Asn His Tyr Arg Met Arg Gly His Ser Pro Phe Ala
 65 70 75 80
 Asn Leu Lys Ser Cys Cys Val Pro Thr Lys Leu Arg Pro Met Ser Met
 85 90 95
 Leu Tyr Tyr Asp Asp Gly Gln Asn Ile Ile Lys Lys Asp Ile Gln Asn
 100 105 110
 Met Ile Val Glu Glu Cys Gly Cys Ser
 115 120

(2) INFORMATION FOR SEQ ID NO:20:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 120 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(vii) IMMEDIATE SOURCE:

- (B) CLONE: Inhibin betaB

(ix) FEATURE:

- (A) NAME/KEY: Protein
- (B) LOCATION: 1..120

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

Arg Ile Arg Lys Arg Gly Leu Glu Cys Asp Gly Arg Thr Asn Leu Cys
 1 5 10 15
 Cys Arg Gln Gln Phe Phe Ile Asp Phe Arg Leu Ile Gly Trp Asn Asp
 20 25 30
 Trp Ile Ile Ala Pro Thr Gly Tyr Tyr Gly Asn Tyr Cys Glu Gly Ser
 35 40 45
 Cys Pro Ala Tyr Leu Ala Gly Val Pro Gly Ser Ala Ser Ser Phe His
 50 55 60
 Thr Ala Val Val Asn Gln Tyr Arg Met Arg Gly Leu Asn Pro Gly Thr
 65 70 75 80
 Val Asn Ser Cys Cys Ile Pro Thr Lys Leu Ser Thr Met Ser Met Leu
 85 90 95
 Tyr Phe Asp Asp Glu Tyr Asn Ile Val Lys Arg Asp Val Pro Asn Met
 100 105 110

WO 99/17797

PCT/US98/21199

18

Ile Val Glu Glu Cys Gly Cys Ala
 115 120

(2) INFORMATION FOR SEQ ID NO:21:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 114 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(vii) IMMEDIATE SOURCE:
 (B) CLONE: TGF-beta1

(ix) FEATURE:
 (A) NAME/KEY: Protein
 (B) LOCATION: 1..114

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

Arg Arg Ala Leu Asp Thr Asn Tyr Cys Phe Ser Ser Thr Glu Lys Asn
 1 5 10 15
 Cys Cys Val Arg Gln Leu Tyr Ile Asp Phe Arg Lys Asp Leu Gly Trp
 20 25 30
 Lys Trp Ile His Glu Pro Lys Gly Tyr His Ala Asn Phe Cys Leu Gly
 35 40 45
 Pro Cys Pro Tyr Ile Trp Ser Leu Asp Thr Gln Tyr Ser Lys Val Leu
 50 55 60
 Ala Leu Tyr Asn Gln His Asn Pro Gly Ala Ser Ala Ala Pro Cys Cys
 65 70 75 80
 Val Pro Gln Ala Leu Glu Pro Leu Pro Ile Val Tyr Tyr Val Gly Arg
 85 90 95
 Lys Pro Lys Val Glu Gln Leu Ser Asn Met Ile Val Arg Ser Cys Lys
 100 105 110
 Cys Ser

(2) INFORMATION FOR SEQ ID NO:22:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 114 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(vii) IMMEDIATE SOURCE:

(B) CLONE: TGF-beta2

(ix) FEATURE:

(A) NAME/KEY: Protein

(B) LOCATION: 1..114

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

```

Lys Arg Ala Leu Asp Ala Ala Tyr Cys Phe Arg Asn Val Gln Asp Asn
1          5          10          15
Cys Cys Leu Arg Pro Leu Tyr Ile Asp Phe Lys Arg Asp Leu Gly Trp
20          25          30
Lys Trp Ile His Glu Pro Lys Gly Tyr Asn Ala Asn Phe Cys Ala Gly
35          40          45
Ala Cys Pro Tyr Leu Trp Ser Ser Asp Thr Gln His Ser Arg Val Leu
50          55          60
Ser Leu Tyr Asn Thr Ile Asn Pro Glu Ala Ser Ala Ser Pro Cys Cys
65          70          75          80
Val Ser Gln Asp Leu Glu Pro Leu Thr Ile Leu Tyr Tyr Ile Gly Lys
85          90          95
Thr Pro Lys Ile Glu Gln Leu Ser Asn Met Ile Val Lys Ser Cys Lys
100         105         110

Cys Ser

```

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 114 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(vii) IMMEDIATE SOURCE:

(B) CLONE: TGF-beta3

(ix) FEATURE:

(A) NAME/KEY: Protein

(B) LOCATION: 1..114

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

```

Lys Arg Ala Leu Asp Thr Asn Tyr Cys Phe Arg Asn Leu Glu Glu Asn
1          5          10          15
Cys Cys Val Arg Pro Leu Tyr Ile Asp Phe Arg Gln Asp Leu Gly Trp
20          25          30
Lys Trp Val His Glu Pro Lys Gly Tyr Tyr Ala Asn Phe Cys Ser Gly
35          40          45

```

WO 99/17797

PCT/US98/21199

20

Pro Cys Pro Tyr Leu Arg Ser Ala Asp Thr Thr His Ser Thr Val Leu
50 55 60

Gly Leu Tyr Asn Thr Leu Asn Pro Glu Ala Ser Ala Ser Pro Cys Cys
65 70 75 80

Val Pro Gln Asp Leu Glu Pro Leu Thr Ile Leu Tyr Tyr Val Gly Arg
85 90 95

Thr Pro Lys Val Glu Gln Leu Ser Asn Met Val Val Lys Ser Cys Lys
100 105 110

Cys Ser

(2) INFORMATION FOR SEQ ID NO:24:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 116 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(vii) IMMEDIATE SOURCE:
(B) CLONE: TGF-beta4

(ix) FEATURE:
(A) NAME/KEY: Protein
(B) LOCATION: 1..116

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

Arg Arg Asp Leu Asp Thr Asp Tyr Cys Phe Gly Pro Gly Thr Asp Glu
1 5 10 15

Lys Asn Cys Cys Val Arg Pro Leu Tyr Ile Asp Phe Arg Lys Asp Leu
20 25 30

Gln Trp Lys Trp Ile His Glu Pro Lys Gly Tyr Met Ala Asn Phe Cys
35 40 45

Met Gly Pro Cys Pro Tyr Ile Trp Ser Ala Asp Thr Gln Tyr Thr Lys
50 55 60

Val Leu Ala Leu Tyr Asn Gln His Asn Pro Gly Ala Ser Ala Ala Pro
65 70 75 80

Cys Cys Val Pro Gln Thr Leu Asp Pro Leu Pro Ile Ile Tyr Tyr Val
85 90 95

Gly Arg Asn Val Arg Val Glu Gln Leu Ser Asn Met Val Val Arg Ala
100 105 110

Cys Lys Cys Ser
115

(2) INFORMATION FOR SEQ ID NO:25:

- (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 114 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(vii) IMMEDIATE SOURCE:

(B) CLONE: TGF-beta5

(ix) FEATURE:

(A) NAME/KEY: Protein

(B) LOCATION: 1..114

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

```

Lys Arg Gly Val Gly Gln Glu Tyr Cys Phe Gly Asn Asn Gly Pro Asn
1           5           10           15
Cys Cys Val Lys Pro Leu Tyr Ile Asn Phe Arg Lys Asp Leu Gly Trp
          20           25           30
Lys Trp Ile His Glu Pro Lys Gly Tyr Glu Ala Asn Tyr Cys Leu Gly
          35           40           45
Asn Cys Pro Tyr Ile Trp Ser Met Asp Thr Gln Tyr Ser Lys Val Leu
          50           55           60
Ser Leu Tyr Asn Gln Asn Asn Pro Gly Ala Ser Ile Ser Pro Cys Cys
          65           70           75           80
Val Pro Asp Val Leu Glu Pro Leu Pro Ile Ile Tyr Tyr Val Gly Arg
          85           90           95
Thr Ala Lys Val Glu Gln Leu Ser Asn Met Val Val Arg Ser Cys Asn
          100          105          110
Cys Ser

```

(2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 454 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(vii) IMMEDIATE SOURCE:

(B) CLONE: Human GDF-9

(ix) FEATURE:

(A) NAME/KEY: Protein

(B) LOCATION: 1..454

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

WO 99/17797

PCT/US98/21199

22

Met 1	Ala	Arg	Pro	Asn 5	Lys	Phe	Leu	Leu	Trp 10	Phe	Cys	Cys	Phe	Ala 15	Trp
Leu	Cys	Phe	Pro 20	Ile	Ser	Leu	Gly	Ser 25	Gln	Ala	Ser	Gly 30	Gly	Glu	Ala
Gln	Ile	Ala 35	Ala	Ser	Ala	Glu	Leu 40	Glu	Ser	Gly	Ala	Met 45	Pro	Trp	Ser
Leu 50	Leu	Gln	His	Ile	Asp	Glu 55	Arg	Asp	Arg	Ala	Gly 60	Leu	Leu	Pro	Ala
Leu 65	Phe	Lys	Val	Leu	Ser 70	Val	Gly	Arg	Gly	Gly 75	Ser	Pro	Arg	Leu	Gln 80
Pro	Asp	Ser	Arg	Ala 85	Leu	His	Tyr	Met	Lys 90	Lys	Leu	Tyr	Lys	Thr 95	Tyr
Ala	Thr	Lys	Glu 100	Gly	Ile	Pro	Lys	Ser 105	Asn	Arg	Ser	His	Leu 110	Tyr	Asn
Thr	Val	Arg 115	Leu	Phe	Thr	Pro	Cys 120	Thr	Arg	His	Lys	Gln 125	Ala	Pro	Gly
Asp 130	Gln	Val	Thr	Gly	Ile	Leu 135	Pro	Ser	Val	Glu	Leu 140	Leu	Phe	Asn	Leu
Asp 145	Arg	Ile	Thr	Thr	Val 150	Glu	His	Leu	Leu	Lys 155	Ser	Val	Leu	Leu	Tyr 160
Asn	Ile	Asn	Asn	Ser 165	Val	Ser	Phe	Ser 170	Ser	Ala	Val	Lys	Cys	Val 175	Cys
Asn	Leu	Met	Ile 180	Lys	Glu	Pro	Lys	Ser 185	Ser	Ser	Arg	Thr	Leu 190	Gly	Arg
Ala	Pro	Tyr 195	Ser	Phe	Thr	Phe	Asn 200	Ser	Gln	Phe	Glu	Phe 205	Gly	Lys	Lys
His	Lys 210	Trp	Ile	Gln	Ile	Asp 215	Val	Thr	Ser	Leu 220	Leu	Gln	Pro	Leu	Val
Ala 225	Ser	Asn	Lys	Arg	Ser 230	Ile	His	Met	Ser	Ile 235	Asn	Phe	Thr	Cys	Met 240
Lys	Asp	Gln	Leu	Glu 245	His	Pro	Ser	Ala	Gln 250	Asn	Gly	Leu	Phe	Asn 255	Met
Thr	Leu	Val	Ser 260	Pro	Ser	Leu	Ile	Leu 265	Tyr	Leu	Asn	Asp	Thr 270	Ser	Ala
Gln	Ala	Tyr 275	His	Ser	Trp	Tyr	Ser 280	Leu	His	Tyr	Lys	Arg 285	Arg	Pro	Ser
Gln 290	Gly	Pro	Asp	Gln	Glu	Arg 295	Ser	Leu	Ser	Ala	Tyr 300	Pro	Val	Gly	Glu
Glu 305	Ala	Ala	Glu	Asp	Gly 310	Arg	Ser	Ser	His	His 315	Arg	His	Arg	Arg	Gly 320
Gln	Glu	Thr	Val	Ser 325	Ser	Glu	Leu	Lys	Lys 330	Pro	Leu	Gly	Pro	Ala 335	Ser

WO 99/17797

PCT/US98/21199

23

Phe Asn Leu Ser Glu Tyr Phe Arg Gln Phe Leu Leu Pro Gln Asn Glu
340 345 350

Cys Glu Leu His Asp Phe Arg Leu Ser Phe Ser Gln Leu Lys Trp Asp
355 360 365

Asn Trp Ile Val Ala Pro His Arg Tyr Asn Pro Arg Tyr Cys Lys Gly
370 375 380

Asp Cys Pro Arg Ala Val Gly His Arg Tyr Gly Ser Pro Val His Thr
385 390 395 400

Met Val Gln Asn Ile Ile Tyr Glu Lys Leu Asp Ser Ser Val Pro Arg
405 410 415

Pro Ser Cys Val Pro Ala Lys Tyr Ser Pro Leu Ser Val Leu Thr Ile
420 425 430

Glu Pro Asp Gly Ser Ile Ala Tyr Lys Glu Tyr Glu Asp Met Ile Ala
435 440 445

Thr Lys Cys Thr Cys Arg--
450

CLAIMS

1. A method for inhibiting oocyte maturation comprising contacting oocytes with an inhibiting effective amount of an inhibitor of GDF-9, thereby inhibiting oocyte maturation as compared to untreated oocytes.
2. The method of claim 1, wherein the inhibitor is a GDF-9 antibody or fragment thereof.
3. The method of claim 2, wherein the antibody is a monoclonal antibody.
4. The method of claim 3, wherein the antibody is a humanized antibody.
5. The method of claim 2, wherein the antibody is administered to a subject *in vivo*.
6. The method of claim 2, wherein the antibody is administered in a dose range of about 0.1 ug to 100 mg.
7. The method of claim 1, wherein the inhibitor is a GDF-9 antisense molecule.
8. A method for inducing an immune response in a subject to GDF-9 whereby oocyte maturation is inhibited, comprising administering to a subject GDF-9 polypeptide or immunogenic fragment thereof and inducing an anti-GDF-9 immune response in the subject.
9. The method of claim 8, wherein the GDF-9 polypeptide or fragment thereof is administered with an adjuvant.
10. The method of claim 8, wherein the GDF-9 polypeptide or fragment thereof is administered by injection or by implantation in a slow release delivery vehicle.

11. The method of claim 8, wherein the GDF-9 polypeptide or fragment thereof is administered in a dose range of about 0.1 ug to 100 mg.

- 1.7 kb

ADRENAL
PANCREAS
INTESTINE
SPLEEN
KIDNEY
LUNG
HEART
BRAIN
OVARY
LIVER
THYMUS
UTERUS
SEMINAL VESICLE
TESTIS
10.5 d PLACENTA



FIG. 1

1 ATGCGTTCCCTTCTTAGTTCCTCCCAAGTCATGGCACTTCCCAAGCAACTTCCCTGTGCGGGT 60
M A L P S N F L L G V
61 TTGCTGCTTTGCCCTGGCTGTGTTTCTTAGTAGCCCTTAGCTCTCAGGCTTCTACTGAAGA 120
C C F A W L C F L S S L S S Q A S T E E
121 ATCCCAGAGTCGAGCCAGTGAAATGTGGAGTCTGAGGCAGACCCCTGGTCCTTGCTGCT 180
S Q S G A S E N V E S E A D P W S L L L
181 GCCGTAGATGGGACTGACAGGTCTGGCCCTCTTCCCCCCCCCTCTTTAAGGTTCTATCTGA 240
P V D G T D R S G L L P P L F K V L S D
241 TAGGCGAGGTGAGACCCCTAAGCTGCAGCCTGACTCCAGAGCACTCTACTACATGA AAA 300
R R G E T P K L Q P D S R A L Y Y M K K
301 GCTCTATAAGACGTATGCTACCAAGAGGGGGTTCCTCCAAACCCAGCAGAGTCACCTCTA 360
L Y K T Y A T K E G V P K P S R S H L Y
361 CAATACCGTCCGGCTCTTCAGTCCCTGTGCCCCAGCAAGAGCAGGCCAGCAACCAGGT 420
N T V R L F S P C A Q Q E Q A P S N Q V
421 GACAGACCGCTGCCGATGGTGGACCTGCTGTTTAACCTGGACCGGTGACTGCCATGGA 480
T G P L P M V D L L L F N L D R V T A M E
481 ACACTTGCTCAAAATCGGTCTTGCTATACACTCTGAACAACCTTGCCTCTTCCCTCCAC 540
H L L K S V L L Y T L N N S A S S S T
541 TGTGACCTGTATGTGTGACCTTGTGGTAAGGAGGCCATGTCTTCTGGCAGGCGACCCCC 600
V T C M C D L V V K E A M S S G R A P P

2/15

FIG.2a

601 AAGAGCACCGTACTCATTCACCCCTGAAGAAACACAGATGCATTGAGATGATGTGACCTC 660
R A P Y S F T L K K H R W I E I D V T S
661 CCTCCTTCAGCCCCCTAGTGACCTCCAGCGAGAGCATTCACCTGCTCTGTCAATTTTTAC 720
L L Q P L V T S S E R S I H L S V [N F T]
721 ATGCACAAAGACCAGGTGCCAGAGGACGGAGTGTTTAGCATGCCCTCTCTCAGTGCCTCC 780
C T K D Q V P E D G V F S M P L S V P P
781 TTCCCTCATCTTGTATCTCAACGACACAAGCACCCAGCCCTACCACCTCTTGGCAGTCTCT 840
S L I L Y L [N D T] S T Q A Y H S W Q S L
841 TCAGTCCACCTGGAGGCCCTTTACAGCATCCCCGCCAGGCCGGTGCTGGCTGCCCGTCCCCGT 900
Q S T W R P L Q H P G Q A G V A A R P V
901 GAAAGAGGAAGCTACTGAGGTGGAAAGATCTCCCCGCCCGTCGAGGCGAGAAAGCCAT 960 3/15
K E E A T E V E R S P [R R R R] G Q K A I
961 CCGCTCCGAAGCGAAGGGCCACTTCTTACAGCATCTTCAACCTCAGCGAATACTTCAA 1020
R S E A K G P L L T A S F [N L S] E Y F K
1021 ACAGTTTCTTTTCCCCCAAAACGAGTGTCAACTCCATGACTTCAGACTGAGTTTGTAGTCA 1080
Q F L F P Q N E C E L H D F R L S F S Q
1081 GCTCAAATGGGACAACCTGGATCGTGGCCCCCGCACAGGTACAAACCCTAGGTACTGTAAAGG 1140
L K W D N W I V A P H R Y N P R Y C K G

FIG.2b

4/15

1141	GGACTGTCCTAGGGCGGTCAGGCCATCGGTATGGCTCTCCTGTGCAACCATGGTCCAGAA	1200
	D C P R A V R H R Y G S P V H T M V Q N	
1201	TATAATCTATGAGAAGCTGGACCCCTTCAGTGCCCAAGGCCCTTCGTGTGTCGGGCAAGTA	1260
	I I Y E K L D P S V P R P S C V P G K Y	
1261	CAGCCCCCTGAGTGTGTGACCATTGAACCCGACGGCTCCATCGCTTACAAAGAGTACGA	1320
	S P L S V L T I E P D G S I A Y K E Y E	
1321	AGACATGATAGCTACGAGGTGCACCTGTCGTTAGCATGGGGCCACTTCAACAAGCCTGC	1380
	D M I A T R C T C R *	
1381	CTGGCAGAGCAATGCTGTGGCCCTTAGAGTGCCCTGGCAGAGAGCTTCCTGTGACCAGTC	1440
1441	TCGCCGTGCTCAGTGCACACTGTGTGACCGGGGAAGTGTGTGTGTGTCATGACCA	1500
1501	CATCGAGTGCAGTGTCCGTAGGTGTAAGGCCACACTGCTCGTTGCCATAAACC AA	1560
1561	GTGAAATGTAACTCATTTGGAGAGCTCTTTCTCCCCACGAGTGTAGTTTTCAGTGCACAG	1620
1621	ATTGTGTAGCATAAGTCTCGAGTAGAATGTAGCTGTGAACATGTCAGAGTGTGTGCTTT	1680
1681	TATGTGACCGAAGAA <u>TAAACTGTTCATGCCAT</u> 1712	

FIG.2c

GDF-3	KRRAA	ISVPKGFC--	--RNF	CHRHQLFINF-QDLGWHKWV	IAPKGF	MANYCHGE	CFFSMTTYLNS--
GDF-9	FNLSEY	FKQFLFP--	--QNE	ELHDFRLSF-SQLKWD	NWIVAPHRYN	PRYCKGD	CPRAVHRHYGS--
GDF-1	PRRDAE	PVLGGGP--	--CGA	RRRLVVSF-REVGWHRWV	IAPRGFLANY	CQGC	ALPVALSGSGGP
Vg-1	RRKRSY	SKLPFTA--	--SNI	CKKRHLVVEF-KDVGWQNWV	IAPQGYMANY	CYGE	PYPLTEILNG--
Vgr-1	RVSSAS	DYNSSEL--	--KTA	CRKHELYVSF-QDLGWQDWI	IAPKGYAANY	CDGE	SFPLNAHMNA--
OP-1	RMANVA	ENSSEDQ--	--RQA	CKKHELYVSF-RDLGWQDWI	IAPEGYAAYY	CEGE	AFPLNSYMNA--
BMP-5	RMSSVG	DYNTSEQ--	--KQA	CKKHELYVSF-RDLGWQDWI	IAPEGYAAFY	CDGE	SFPLNAHMNA--
60A	SPNNVPL	LEPMES--	--TRS	QMOTLYIDF-KDLGWHDWI	IAPEGYGAFY	CSGE	NFPLNAHMNA--
BMP-2	EKRQAK	HKQRKRL--	--KSS	CKRHPLYVDF-SDVGWNDWIV	APPGYHAFY	CHGE	PFPLADHLNS--
BMP-4	RSPKHH	SQARKK--	--NKN	ORRHSLYVDF-SDVGWNDWIV	APPGYQAFY	CHGD	PFPLADHLNS--
DPP	KRHARR	PTRRKNH--	--DDT	ORRHSLYVDF-SDVGWDDWIV	APLGDAYY	CHGK	PFPLADHFNS--
BMP-3	QTLKKA	RRKQWIE--	--PRN	ARRYLKVDF-ADIGWSEW	IISPKSFDAYY	CSGA	QFPMPSLKP--
MIS	PGRAQR	SAGATAA--	--DGP	ALRELSVDL---RAERSVLI	PETYQANN	CQVC	GWQSDRNPRY-
Inhibin α	LRLLQR	PEEPAA--	--HAN	CHRVALNISF-QELGWERWIV	PPSFIFHY	CHGC	GLHIPPNLSLPV
Inhibin βA	RRRRRG	LECDGKV--	--NI	CKKQFFVSF-KDIGWNDW	IAPSGYHANY	CEGE	PSHIAGTSGSSL
Inhibin βB	RIRKRG	LECDGRT--	--NL	CRQQFFIDF-RLIGWNDW	IAPTGYGNY	CEGS	PAYLAGVPGSAS
TGF-β1	RRALDT	NYCFSST--	--EKN	CVRQLYIDFRKDLGWK-WI	HEPKGYHANF	CLGF	CPYIWSLD----
TGF-β2	KRALDA	AYCFRNV--	--QDN	CLRPLYIDFRKDLGWK-WI	HEPKGYNANF	CAGA	CPYLWSSD----
TGF-β3	KRALDT	NYCFRNL--	--EEN	CVRPLYIDFRQDLGWK-WV	HEPKGYANF	CSGF	CPYLRSD----
TGF-β4	RRDLDT	DYCFGPGTDEKN	--CVR	PLYIDFRKDLQWK-WI	HEPKGYMANF	CMGF	CPYIWSAD----
TGF-β5	KRGVGQ	EYCFGNN--	--GPN	CVKPLYINFRKDLGWK-WI	HEPKGYEANY	CLGN	CPYIWSMD----

FIG.3a

GDF-3	---
GDF-9	---PVHTMVQNI IYE---KLDPSVPRPSCN---PGKYSPLSVLTI--EPDGSIA YKEYEDMIATRC---
GDF-1	PALNHA VLRALMHA--AAPGAADLFCNV--PARLSPI SVLFF--DNSDNVVL RQYEDMVVDE---
Vg-1	---SNHAILQTLVHS---IEPEDIPLFCNV---PTKMSPISMLFY--DNNDNVVL RHYENMAVDE---
Vgr-1	---TNHAI VQTLVHL---MNPEYVPKFCNA---PTKLNAI SVLYF--DDNSNVIL KKYRNMMVRA---
OP-1	---TNHAI VQTLVHF---INPETVPKFCNA---PTQLNAI SVLYF--DDSSNVIL KKYRNMMVRA---
BMP-5	---TNHAI VQTLVHL---MFPDHVPKFCNA---PTKLNAI SVLYF--DDSSNVIL KKYRNMMVRS---
60A	---TNHAI VQTLVHL---LEPKKVPKFCNA---PTRLGAL PVL YH--LNDENVNL KKYRNMI VKS---
BMP-2	---TNHAI VQTLVNS---VNSKI PKACCV---PTELSAI SMLYL--DENEKVVL KNYQDMVVE---
BMP-4	---TNHAI VQTLVNS---VNSSI PKACCV---PTELSAI SMLYL--DEYDKVVL KNYQEMVVE---
DPP	---TNHAVVQTLVNN---MNP GKVPKACCV---PTQLDSVAML YL--NDQSTVVL KNYQEMTVVC---
BMP-3	---SNHATI QSI VRA--VGVVPGI PEFCNV---PEKMSSL SILFF--DENKNVVL KVYPNMTVES---
MIS	---GNHVVL LKMQA---RGAALARPFCNV---PTAYAGKLLISLSEER--ISAHHVPNMVATE---
Inhibin α	---PGAPPTPAQPYS---LLPGAQPFCCNAALPGTMRPLHVRTTSDGYSFKYETVPNLLTQH---
Inhibin β A	---SFHSTVINHYRMRGHSPFANLKSCCV---PTKLRPMSML Y--DDGQNI IKKDIQNMI VEE---
Inhibin β B	---SFHTAVVNQYRMRLNPGT--VNSCCI---PTKLSTMSML YF--DDEYNI VKRDVPNMIVEE---
TGF- β 1	---TQYSKVLALYNQ---HNPGASAPFCNV---PQALEPLPI VY--VGRKPKV--EQLSNMIVRS---
TGF- β 2	---TQH SRVLSLYNT---INPEASAPFCNV---SQDLEPLTIL Y--IGKTPKI--EQLSNMIVKS---
TGF- β 3	---TTHSTVLGLYNT---LNPEASAPFCNV---PQDLEPLTIL Y--VGRTPKV--EQLSNMIVKS---
TGF- β 4	---TQYTKVLALYNQ---HNPGASAPFCNV---PQTL DPLPI IY--VGRNVRV--EQLSNMIVRA---
TGF- β 5	---TQYSKVLSLYNQ---NNPGASISPCNV---PDVLEPLPI IY--VGR TAKV--EQLSNMIVRS---

FIG.3b

8/15

[illegible]

FIG. 4b




FIG. 5c




FIG. 5b




FIG. 5a

10/15

```

1 MALPSNFLLGVCFAWLCFLSSLSSQASTEESQSGASENVESEADPWSLL 50
  || | ||| ||||| || ||| | | ||| |||
1 MARPNKFLWFCFAWLCFPISLGSQASGGEAQIAASAELESGAMPWSLL 50

51 LPVDGTDRSGLLPPLFKVLSDRRGETPKLQPDSTRALYMKKLYKTYATKE 100
  | || ||| ||||| || | ||||| |||||
51 QHIDERDRAGLLPALFKVLSVGRGGSFRLQPDSTRALHYMKKLYKTYATKE 100

101 GVPKPSRSHLYNTVRLFSPCAQQEQAPSNOVTGPLPMVDLLFNLDRTAM 150
  | || ||||| || || ||| || | ||||| |
101 GIPKSNRSHLYNTVRLFTFCTRHKQAPGDQVTGILPSVELLFNLDRTTV 150

151 EHLLKSVLLYTLNNSASSSSTVTCMCDLVVKEAMSSGRAPPRAPYSFTL. 199
  ||||| ||| | | | | | || | | |||||
151 EHLLKSVLLYNINNSVSFSSAVKVCNLMIKEPKSSSRTLGRAPYSFTFN 200

200 .....KKHRWIEIDVTSLLQPLVTSSERSIHLSVNFTCTKDQV....PE 239
  ||| || ||||| || | ||| | ||| |||
201 SQFEFGKKHKWIIQIDVTSLLQPLVASNKRSIHMSINFTCMKDQLEHPSAQ 250

240 DGVFSMPLSVPPSLILYLNDTSTQAYHSWQSLQSTWR.FLQHPGA.GVAA 283
  | | | | | ||||| ||||| || | | | | |
251 NGLFNMTL.VS?SLILYLNDTSAQAYHSWYSLHYKRRPSQGPDQERSLSA 299

289 RPYKEEATEVERSP..RRRFGQKAIRSEAKGPLLTASFNLSEYFKQFLFP 336
  || ||| | || |||| | | || ||||| ||| |
300 YPVGEEAAEDGRSSHRRRFGQETVSSELKKPLGPASFNLSEYFRQFLLP 349

337 QNECELHDFRLSFSQLKWDNWIVAPHRYNPRYCKGDPRAVRHRYGSPVH 386
  ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
350 QNECELHDFRLSFSQLKWDNWIVAPHRYNPRYCKGDPRAVGHRYGSPVH 399

387 TMVQNIIEKLDPSVPRPSVPGKYSPLSVLTIEPDGSIAYKEYEDMIAT 436
  ||||| ||||| ||||| ||||| ||||| ||||| |||||
400 TMVQNIIEKLDSSVPRPSVPAKYSPLSVLTIEPDGSIAYKEYEDMIAT 449

437 RQICR 441
  ||||
450 KQICR 454
  ||||

```



648

FIG. 6

908

FIG. 7a



FIG. 7b



FIG. 7c



FIG. 7d



FIG. 8a




FIG. 8b




FIG. 9b




FIG. 9a



FIG. 10a



FIG. 10b



FIG. 11a



FIG. 11b